ï‚·ï‚·
ï‚·Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND 
TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC 
PATIENTS WITH DEVELOPMENTAL AND/OR EPILEPTIC ENCEPHALOPATHIES (ELEKTRA)
Study ID: [REMOVED]
Protocol Approve Date: 14 February 2019
Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from 
view with a 
black/blue bar) to protect either personally identifiable information (PPD) or company confidential 
information (CCI). 
This 
may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 1of 106PROTOCOL TAK-935-2002 (OV935)
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND 
TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN 
PEDIATRIC PATIENTS WITH DEVELOPMENTAL AND/OR EPILEPTIC 
ENCEPHALOPATHIES (ELEKTRA)
Sponsor: Ovid Therapeutics, Inc.
1460 Broadway
New York, NY 10036
Telephone: +1 (646) 661-7661
Sponsor Contact:
Medical Monitor:
Date of Amendment 2: 14 February 2019
Date of Amendment 1: 23 April 2018
Date of Original Protocol: 16 February 2018PPD
Property of Takeda: For Non-Coment 2:nt 2:
ndmentdme
OriiginalginND D 
IC IC
to the Applicable Terms of Use
mmercial Use Only and Subject to
operty of Ta
3URWRFRO7$.29$PHQGPHQW 2YLG7KHUDSHXWLFV,Q F
'DWH)HEUXDU\
3DJH 2RI107 
SPONSOR SIGNATURE PAGE 
PROTOCOL TITLE:  A Phase 2, Multicenter, Randomized, Double-blind, 
Placebo-controlled Study to Evaluate the Ef ficacy, Safety, and Tolerability of TAK-935 
(OV935) as an Adjunctive Therapy in Pedi atric Patients with Developmental and/or 
Epileptic Encephalopathies (ELEKTRA) 
PROTOCOL NUMBER:  TAK-935-2002 (OV935) Amendment 2 
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
'DWH02/13/2019PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBBBBBBBBBd Subject to the Applica
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 3of 106PROTOCOL AMENDMENT 2 SUMMARY OF CHANGES
Rationale for Amendment 2
This document describes the changes in reference to the protocol incorporating Amendment
No.2. The primary reasons for this amendment are to update the study  design (adding 6weeks to 
the treatment duration), change the primary endpo int, change the secondary and exploratory 
endpo ints, revise the inclusio n criteria to cl arify the use of benzodiazepines as antiepileptic 
drugs , and cl arify the cri teria regarding the diagnosis of Dravet syndro me and Lennox -Gastaut 
syndro me. 
Changes Implemented by Amendment 2:
In addit ion to the changes described above, the following changes were also implemented:
ï‚·Clarified that for all clinical studies across the TAK -935 program ,the independent Data 
Moni toring Committee will review the AE profile sof 12 patients aged â‰¥9 years 
completing 4 weeks of treatment of TAK -935 in the TAK -935 program  before opening 
enrollment to younger patients
ï‚·Added history  of confirmed cataract ( untreated wi th surgery ) as an exclusio n criterion 
ï‚·Added perampanel as a prohibited medication
ï‚·Added 2 new forms of approved contraceptive methods
ï‚·Clarified that only  sexually  active female patients of childbearing potential will have 
pregnancy tests performed
ï‚·Clarified the durati on for avoidance of pregnancy and donat ion of sperm  and ovafor 
male and female pat ients, respectively
ï‚·Revised the PK sampling time po ints
Administrative and minor grammat ical, editorial , and f ormatting changes were m ade for 
clarificati on purposes only. A detailed descript ion of and rationale for changes implemented by 
Amendment 2 are provided in Appendix 5.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 4of 106INVESTIGATORâ€™S AGREEMENT
I have received and read the Invest igatorâ€™s Brochure for TAK -935. I have read the
TAK -935-2002 (OV935) Protocol  Amendment 2, dated 11February 2019 , and agree to conduct 
the study  in accordance with this protocol, all applicable government regul ations, the principles 
of the ICH E6 Guidelines for G ood Clinical Practice , and the principles of the World Medical 
Associ ation Declarat ion of Helsinki. I also agree to maintain the confident iality of all 
inform ation received or developed i n connect ion with this protocol .
Printed Name of Invest igator
Signature of Investigator
Date
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 5of 1061. SYNOPSIS
Name of Sponsor/Company:
Ovid Therapeutics, Inc.
Name of Study drug:
TAK-935
Title of Study:
A Phase 2, Multicenter, Randomized, Double -blind, Placebo -controlled Study to Evaluate the Efficacy, 
Safety, and Tolerability of TAK -935 (OV935) as an Adjunctive Therapy in Pediatric Patients with 
Developmental and/or Epileptic Encephalopathies (ELEKTRA)
Study Number: TAK-935- 2002 (OV935) Phase: 2
Study Design:
This is a Phase 2, multicenter, randomized, double -blind, placebo- controlled, parallel -group, study in 
pediatric patients (aged â‰¥2 and â‰¤17 years) with Dravet syndrome and Lennox Gastaut syndrome (LGS) 
demonstrating â‰¥3convulsive or â‰¥4 drop seizures , respectively, per month during the 3 months 
immediately prior to Screening (based on historic alinformation) and â‰¥3 convulsive or â‰¥4 drop seizures , 
respectively, during a minimum of 4 weeks during the prospective Baseline Period (based on the seizure 
diary records). Convulsive seizures include generalized tonic -clonic, focal to bilateral tonic -clonic with 
impair ed awareness, hemi -clonic ,and simultaneous bilateral clonic (generalized clonic) seizures. D rop 
seizures are defined as involving the entire body, trunk, or head that leads to a fall, injury, slumping in a 
chair, or head hitting a surface, or that could have led to a fall or injury, depending on the position of the 
patient at the time of the seiz ure or spell. Examples of seizures causing drop include, but are not limited 
to, atonic, clonic, and tonic seizures.
Approximately 126 patients will be randomized to ensure 112 evaluable patients. Randomization will be 
stratified by 2 categories: patients with Dravet syndrome with convulsive seizures and patients with LGS 
with drop seizures. Stratification will be performed to ensure balance of treatments within each stratum.
The study will begin with a phased enrollment based on age. Patients aged â‰¥9 years will be enrolled first, 
prior to open enrollment in the study, for assessment of safety. The independent Data Monitoring 
Committee (iDMC) will review the adverse event (AE) profile sof the first 12 patients aged â‰¥9 years 
completing 4 weeks of treatment across all ongoing pediatric TAK -935 studies , prior to recommending 
treatment for patients aged <9 years.
Study Periods:
This study consists of 2 main periods:
ï‚·4-to 6-week Screening/Baseline Period
ï‚·20-week Treatment Period
ï€­8-week Dose Optimization Period
ï€­12-week Maintenance Period
The Treatment Period consists of the Dose Optimization Period and Maintenance Period.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 6of 106Dravet syndrome patients who have had on average â‰¥3 convulsive or LGS patients who have had on 
average â‰¥4drop seizures per month during the 3 months immediately prior to Screening (based on the 
historical information) and â‰¥3 convulsive or â‰¥4 drop seizures , respectively, during a minimum of 
4weeks during the Baseline Period (based on the seizure diary records) will be eligible for entry into the
study.
At the end of the 4- week Baseline Period, patients will return to the clinic (Visit 2 ). Seizure diaries will 
be reviewed by the Medical Monitor or delegated staff and if a patient did not meet the eligibility criteria, 
including minimum number of seizures required for the study, the patient will be discontinued from the 
study and considered a screen failure. 
The patients who meet the entry criteria will be randomi zed in a 1:1 ratio to double -blind treatment with 
TAK-935 or matching placebo for the 20-week Treatment Period ( 8-week Dose Optimization Period and 
12-week Maintenance Period).
Dosing and Titration Schedule
All patients will receive TAK -935 twice a day ( BID)orally or via gastrostomy tube (G -tube)/
percutaneous endoscopic gastrostomy (PEG) tube with or without food (patients enrolled in clinical sites 
in China are not to receive study drug via G -tube/PEG tube).
For patients weighing <60 kg, the total daily dose of study drug (either placebo or TAK -935) is 
calculated based on body weight at Visit 1 and will be given BID (Table 1). The selected doses for the 
differ ent weight groups are listed in
 Table 1. For patients weighing â‰¥60 kg at Visit 1, dosing will be 200 
mg/day followed by 400 mg/day, then 600 mg/day 
(Table 1). Study drug can be taken with or without 
food. For patients aged â‰¥9 years at Visit 1, the total daily dose of study drug (either placebo or TAK -935) 
is calculated based on body weight at Visit 1 and will be given BID. Patients will receive the initial dose 
of study drug, Dose 1, for the first 7 days after randomization on Visit 2. In the subsequent phone call 
and visit (phone call 1 [Day 8 ]and Visit 3 [Day 15] ),the study drug dose will be increased to Dose 2 and 
Dose 3. The maximum dose for any patient will be 600 mg/day (300 mg BID). Patients will be contacted 
by phone within the first 2days following escalation to the maximum dose to assess safety and 
tolerability of the study drug. Study drug dose will be allowed to change in first 6 weeks of Dose 
Optimization P eriod,based on the judgment of the Investigator and with the approval of the Medical 
Monitor . The final dose level will be maintained until the end of the Maintenance Period; however, the 
dose may be decreased to the previous lower doses, for safety and t olerability issues. Patients who cannot 
tolerate Dose 1 will be withdrawn from the study (and will complete the early termination and safety 
follow -up visits).
Dosing Schedule by Weight:
Weight 
(kg)Dose 1 Dose 2 Dose 3
(mg/day)aNo. Tablets/ 
Mini -tablets(mg/day)aNo. Tablets/ 
Mini -tablets(mg/day)aNo. Tablets/ 
Mini -tablets
10-14 80 0/4 160 0/8 220 0/11
15-19 120 0/6 200 0/10 260 0/13
20-24 120 0/6 240 0/12 320 0/16
25-29 120 0/6 240 0/12 360 0/18
30-34 160 0/8 280 0/14 400 0/20
35-39 160 0/8 280 0/14 440 0/22
40-44 160 0/8 320 0/16 480 0/24
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 7of 10645-49 200 0/10 360 0/18 480 0/24
50-54 200 0/10 360 0/18 520 0/26
55-59 200 0/10 360 0/18 560 0/28
â‰¥60 200 2/0 400 4/0 600 6/0
aTotal dose administered twice daily.
Pharmacokinetic Assessments:
Pharmacokinetic (PK) sample collection will start at Visit 2 (Day 1), and it is designed to investigate the 
PK in all patients. The first 12 randomized patients aged â‰¥9 years and the first 12 randomized patients 
aged <9 years will receive the first dose of TAK -935 or placebo in the clinic; PK blood draws will occur 
within 1 hour before the morning dose (pre-morning dose)and 30 min ( Â±10 min) and 1, 2, and 4hours 
(Â±10 min) post-morning dose. After Visit 2 (Day 1), additional PK samples will be collected within 
1hour before the morning dose (pre-morning dose) and 30 min (Â±10 min) post-morning dose at Visit s
3, 
4, 5, and 6 during the study.
The remaining randomized patients in the study will receive the first dose of TAK -935 or placebo in the 
clinic, with PK blood draws occurring within 1 hour before the morning dose (pre-morning dose) and 
30min(Â±10 min )post-morning dose at Visit s
2, 3, 4, 5, and 6 during the study.
Concomitant and Prohibited Medications:
Adjunctive antiepileptic drug (AED) treatment, (medical) marijuana, cannabidiol products, vagal nerve 
stimulator (VNS) settings, and ketogenic diet should not be altered during the study. Concurrent 
treatment regimen data will be collected throughout the study.
Use of strong inducers and inhibitors of cytochrome P450 (CYP) 3A4 (prescription medications, OTC 
medications, or dietary supplements) within 30 days before randomization through follow -up is 
prohibited, except for AEDs (e.g., carbamazepine, phenobarbital, phenytoin). Refer to Appendix 4for a 
list of prohibited CYP3A4 inducers and inhibitors.
Use of perampanel from screening through follow -up is prohibited.
Use of traditional Chi nese medicines should be approved by the Medical Monitor at screening.
Following completion of the study, patients will have the option to enroll in a long -term (24-month), 
open -label extension study (under a separate protocol, TAK -935-18-001 [OV935] ) or t o enter a 
double -blind taper period (maximum 14 days). During the taper period, the study drug dose will be de -
escalated to a lower dose (taper Dose 3 to Dose 2, taper Dose 2 to Dose 1) every 3 days or less frequently 
based on Investigatorâ€™s discretion until there is no de -escalation and study drug dose is discontinued. 
After tapering, the patients will complete a Safety Follow -up visit approximately 15 days after the last 
dose of study drug and exit the study. The total study duration from Screening to the last visit in this 
study will be approximately 30 weeks.
An iDMC will monitor the patientsâ€™ safety, in accordance with the iDMC charter.
Procedures:
Daily seizure diaries will be used to determine seizure frequency for the evaluation of efficacy.
Bloo d samples for clinical safety laboratory tests (5 .7mL at each sample time point) ,including 
hematology and chemistry, will be collected at Visit 1 (Screening), Visit 2 (Day 1), Visit 4 (Day 36), and 
at Visit 6 (Day 141) .One blood sample will be collected (2mL for PD assessment) at Visit 7 (Day 169) , 
the follow -up visit. In addition, urinalysis will be performed at the specified visits.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 8of 106Blood samples for PK analysis of TAK -935 and M -I will be drawn within 1 hour of the morning dose 
(pre-morning dose) and 30 min ( Â±10 min) and 1, 2, and 4 hours ( Â±10 min) post-morning dose for the 
first 12 patients aged â‰¥9 years and the first 12 patient s aged < 9 years. After Visit 2 (Day 1), additional 
PK samples will be collected within 1 hour before the morning dose (pre-morning dose) and 30 min 
(Â±10min)post-morning dose at Visits 3, 4, 5, and 6 during the study fro m those patients. The remaining 
randomized patients in the study will receive the first dose of TAK -935 or placebo in the clinic, with PK 
blood draws occurring within 1 hour bef ore the morning dose (pre-morning dose) and 30 min(Â±10 min )
post-morning dose at Visit s2, 3, 4, 5, and 6 during the study.
The total blood volume collected during the study will be approximately 7 3.2mL for patients. The 
maximum blood volume collected during a 30 -day period will be 28.4 mL and maximum blood volume 
collected during a single visit will be 1 4.7 mL. The total blood volume limits are consistent with 
physiological minimal risk as specified by the WHO guidelines.1
Primary Objective:
To investigate the effect on the frequency of all seizures (convulsive and drop) in patients treated with 
TAK-935 as an adjunctive therapy compared to placebo in the Maintenance Period
Secondary Objectives:
ï‚·To investigate the effect on the frequency of al l seizures (convulsive and drop) in patients 
treated with TAK-935 as an adjunctive therapy compared to placebo throughout the Treatment 
Period
ï‚·To investigate the effect on the frequency of convulsive seizure in patients with Dravet 
syndrome treated with TAK-935 as an adjunctive therapy compared to placebo in the 
Maintenance Period
ï‚·To investigate the effect on the frequency of drop seizure in patients with LGS treated with 
TAK-935 as an adjunctive therapy compared to placebo in the Maintenance Period
ï‚·To in vestigate the seizure frequency of LGS patients considered treatment responders 
throughout the Maintenance Period; treatment responders are defined as those with:
ï€­Worsening of 25% or more in drop seizures from baseline
ï€­Worsening of 1% to 25% in drop seizures from baseline
ï€­No change in drop seizures from baseline ( Worsening of 1% to Reduction of 1%)
ï€­Reduction of 25% or more in drop seizures from baseline
ï€­Reduction of 50% or more in drop seizures from baseline
ï€­Reduction of 75% or more in drop seizures from baseline
ï€­Reduction of 100% in drop seizures from baseline
ï‚·To investigate the seizure frequency of Dravet patients considered treatment responders 
throughout the Maintenance Period ;treatment responders are defined as those with :
ï€­Worsening of 25% or more in convulsive seizures from baseline
ï€­Worsening of 1% to 25% in convulsive seizures from baseline
ï€­No change in convulsive seizures from baseline ( Worsening of 1% to Reduction of 1%)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 9of 106âˆ€Reduction of 25% or more in convulsive seizures from baseline
âˆ€Reduction of 50% or more in convulsive seizures from baseline
âˆ€Reduction of 75% or more in convulsive seizures from baseline
âˆ€Reduction of 100% in convulsive seizures from baseline
!To investigate the change in Clinical Global Impression of Severity and Change assessment 
(CGI-S/C) responses of Investigator and Caregiver Clinical Global Impression of Change assessment (Care GI-C) in patients treated with TAK-935 as an adjunctive therapy compared to 
placebo
!To characterize the relationship between plasma 24S-hydroxycholesterol (24HC) levels and 
seizure frequency
Safety Objectives:
!To evaluate safety and tolerability of TAK-935 as adjunctive therapy as compared to placebo
!To investigate the effect on behavior and adaptive function in patients treated with TAK-935 as 
adjunctive therapy compared to placebo using the Vineland Adaptive Behavioral scales (VABS) and Aberrant Behavior Checklist community questionnaire (ABC-C)
!To evaluate the occurrence of myoclonic and atypical absence-free days to determine if there is 
worsening of these seizure types during treatment with TAK-935
Study Population:
Pediatric patients aged â‰¥2 and â‰¤17 years with Dravet syndrome or LGS who are on background AED 
therapyCCI
Property of Takeda: For Non-Commercial Uerabilityrabili
fect on bct on 
comparcomp
ehavior havior
e the occthe oc
ng of theng of U
pulationulatio
ric patiec pati
rapyrapyFplicable Terms of Usepared to ared t
)levels levelofof
ofUse Only and Subject to the Appli
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 10of 106Number of Patients:
Approxim ately 126 male and female patients will 
be randomized to ensure at least 112 eligible 
patients (a minimum of 46 in the Dravet stratum, 
and 80 in the LGS stratum).Number of Sites:
Estimated total: approximately 45 sites globally
Study Drug:
Patients will be dosed with either TAK -935 or 
matching placeboRoute of Administration:
Oral or via gastrostomy tube (G -tube)/
percutaneous endoscopic gastrostomy ( PEG) 
tube.
Note: Patients enrolled in clinical sites 
inChina are not to receive study drug via 
G-tube/PEG tube.
Twice daily
Duration of Treatment:
20weeks plus 2 -week taperPeriod of Evaluation:
~30 weeks (includes 4-to 6-week 
Screening/Baseline period, 20-week 
double -blind treatment period [
8-week Dose 
Optimization Period and 12- week Maintenance
Period ], 2-week taper ,and 2 -week safety follow -
up period)
Main Criteria for Inclusion:
1.The patient and patientâ€™s legal representative (i .e., parent or legal guardian )are willing and 
able to read, understand, and sign the informed consent form and assent, if applicable
2.Male and female patients aged â‰¥2 and â‰¤17 years at the time of informed consent and the first 
dose of study drug
3.Clinical diagnosis of LGS and a history of, on average, â‰¥4 drop seizures per month during the 
3 months immediately prior to Screening based on historic alinformation, and the patient has 
â‰¥4 drop seizures during a minimum of 4 weeks of seizure data collection during the 
prospective Baseline Perio d
-OR -
Clinical diagnosis of Dravet syndrome and a history of, on average, â‰¥3 convulsive seizures per 
month during the past 3 months based on the historic alinformation, and the patient has â‰¥3 
convulsive seizures during a minimum of 4 weeks of seizure data collection during the 
prospective Baseline Period
4.Weight of â‰¥10 kg at the Screening visit (Visit 1)
5.Currently taking 1 to 4 AEDs at a stable dose for 4 wee ks prior to the Screening visit (Visit 1); 
benzodiazepines used chronically (on daily frequency) to treat seizures are considered AED s
6.If using a VNS, must have VNS placed at least 3 months prior to the Screening visit with 
stable settings for >1 month; VN S parameters must remain constant throughout the study 
(VNS will not be counted as an AED)
7.If on a ketogenic diet, must have started the ketogenic diet at least 3 months prior to the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 11of 106Screening visit (Visit 1), diet should be stable for 4 weeks before the S creening visit (Visit 1); 
and should continue through the duration of the study (ketogenic diet will not be counted as an 
AED)
8.Failed to become and remain seizure free with trials of at least 2 AEDs
9.The patient and patientâ€™s legal representative (i .e., parent or legal guardian )are willing to keep 
the AED, VNS, and ketogenic diet regimen(s) stable throughout the study
10.The patient is able to carry out all appropriate assessment and take study drug in the opinion of 
the Investigator and parent/caregiver
11.The p atient has a documented clinical diagnosis of Dravet syndrome or LGS: 
Diagnosis of Dravet syndrome supported by:
ï‚·Onset of seizures around 6 months of age
ï‚·Initial seizures
- F ever-induced or fever -triggered seizures
-Hemiclonic or generalized tonic seizures
- P rolonged seizures (approximately 15 minutes or longer, some >30 min)
ï‚·Between 1 and 5 years, other seizure types emerge:
-Myoclonic seizures
-Focal awareness altered
-Absence
-Non-convulsive status (absence or myoclonic)
-Convulsive status epilepticus
ï‚·Developmen t norm al within 1styear of life , then intellectual disability emerges
-May regress with recurrent status epilepticus
Diagnosis of Lennox -Gastaut syndrome supported by:
ï‚·History of abnormal EEG consistent with LGS 
-EEG with slow and/or disorganized background AND one of the following:
oEEG with bursts of generalized 2.5 Hz (or less) spike and wave activity, OR
oGeneralized paroxysmal fast activity (GPFA)
ï‚·Greater than 1 type of generalized seizure for at least 6 months
-At least 1 seizure type with drop seizures
ï‚·Less than 11 years of age at the onset of LGS
-Evidence of development delay or regression OR history of special education classed 
OR measured IQ <70
12.Sexually active female patients of childbearing potential (defined as first menarche) must agree 
to use a highly effective method of birth control during the study and for 30days following the 
last dose of study drug
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 12of 106Main Criteria for Exclusion:
Patients will be excluded from study enrollment if they meet any of the following criteria:
1. T he patient has been admitted to a medical facility and intubated for treatment of status 
epilepticus 2 or more times in the 3 months immediately prior to the screening visit
2.Non-epileptic events that cannot be reliably distinguished from epileptic seizures (e .g., 
gastro esophageal reflux, muscle cramps, etc.)
3.Patient s with history of confirmed cataract (untreated with surgery)
4.Unstable, clinically significant neurologic (other than the disease being studied), psychiatric, 
cardiovascular, ophthalmologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, 
urologic, immunologic, hematopoietic, endocrine disease, malignancy including progressive 
tumors, or other abnormality, which may impact the ability to participate in the study or that 
may potentially confound t he study results. It is the responsibility of the Investigator to assess 
the clinical significance; however, consultation with the Medical Monitor may be warranted
5.Any history of alcohol, opioid, or other drug use disorder, as per the Diagnostic and Statis tical 
Manual of Mental Disorders, Fifth Edition (DSM- V), within the 2 years immediately prior to 
the Screening visit (Visit 1)
6.Suicide attempt within the last year, at significant risk of suicide (either in the opinion of the 
Investigator or defined as â€˜ye sâ€™ to suicidal ideation question 4 or 5 on the Columbia -Suicide 
Severity Rating Scale [C -SSRS] at Screening) or appearing suicidal per Investigator judgment
7.History of human immunodeficiency virus (HIV) infection (patient who has tested positive for 
huma n immunodeficiency virus antibodies (HIV) -1/2Ab), or history o
f active hepatitis B, or 
active hepatitis C infection. (Note that patients who have been vaccinated against hepatitis B 
[hepatitis B surface antibody {Ab} -positive] who are negative for other mark ers of prior 
hepatitis B infection [eg, negative for hepatitis B Core Ab] are eligible )
8.Abnormal and clinically significant ECG abnormality at Screening
a.QT interval with Fridericiaâ€™s correction method (QTcF) >450 ms (males) or >470 ms 
(fema les), confirmed with one repeat testing, at the Screening visit
9.Abnormal clinical laboratory test results at the Screening visit that suggest a clinically 
significant underlying disease that would compromise the well -being of the patient (if the 
patient has alanine aminot ransferase [ALT] and/or aspartate aminotransferase [AST] 
>2.5 Ã—the upper limit of normal [ULN], the Medical Monitor should be consulted)
10.Participated in a clinical study involving another study drug in the previous month (or 5 half-
lives of the study drug , whichever is longer) or currently receiving another study drug
11.Received TAK -935 in a previous clinical study or as a therapeutic agent
12.Immediate family members, or in a dependent relationship with a study site employee who is 
involved in the conduct of t his study (eg, child, sibling)
13.Known hypersensitivity to any component of the TAK -935 formulation
14.Currently pregnant or breastfeeding or is planning to become pregnant within 90 days of the 
last dose of study drug
Endpoints:
Primary Efficacy Endpoint
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 13of 106!Percent change from Baseline in seizure frequency per 28 days (based only on convulsive 
seizures for the patients in the Dravet syndrome stratum and drop seizures for the patients in the LGS stratum) in patients receiving TAK-935 as compared to placebo during the Maintenance Period
Secondary Efficacy Endpoints
!Percent change from Baseline in seizure frequency per 28 days (based only on convulsive 
seizures for the patients in the Dravet syndrome stratum and drop seizures for the patients in the LGS stratum) in patients receiving TAK-935 as compared to placebo during the Treatment 
Period
!Percent change from Baseline in convulsive seizure frequency per 28 days in patients 
randomized to the Dravet syndrome stratum and receiving TAK-935 as compared to placebo during the Maintenance Period
!Percent change from Baseline in drop seizure frequency per 28 days in patients randomized to 
the LGS stratum and receiving TAK-935 as compared to placebo during the Maintenance Period
!Proportion of patients in the LGS stratum considered treatment responders throughout the 
Maintenance Period; treatment responders defined as those with: 
- Worsening of 25% or more in drop seizures from baseline
- Worsening of 1% to 25% in drop seizures from baseline
- No change in drop s eizures from baseline (Worsening of 1% to Reduction of 1%)
- Reduction of 25% or more in  drop seizures from baseline
- Reduction of 50% or more in  drop seizures from baseline
- Reduction of 75% or more in  drop seizures from baseline
- Reduction of 100% in drop seizures from baseline
!Proportion of patients in the Dravet syndrome stratum considered treatment responders 
throughout the Maintenance Period; treatment re sponders are defined as those with:
- Worsening of 25% or more in convulsive seizures from baseline- Worsening of 1% to 25% in convulsive seizures from baseline- No change in convulsive seizures from baseline (Worsening of 1% to Reduction of 1%)
- Reduction of 25% or more in convulsive seizures from baseline
- Reduction of 50% or more in convulsive seizures from baseline- Reduction of 75% or more in convulsive seizures from baseline- Reduction of 100% in convulsive seizures from baseline
!Change in CGI-S/C responses of Investigator reported impression of efficacy and tolerability of 
study drug
!Change in Care GI-C responses of parent/family reported impression of efficacy and tolerability 
of study drug
!To characterize plasma 24HC levels and change in seizure frequency in patients treated with 
TAK-935 as an adjunctive therapy
CCIProperty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms ofn the the 
nt 
ents ents 
red to pled to p
patients atients
ring the ng th
respondeespond
ith: th: 
baselineaseline
m bbaselinaselin
Worseninorsen
res s fromfro
izures zure f
pseizurseizu
izures izures f
vet syndet syn
eriod; trriod; 
or moremo
% to 25%% to 2
n n convuconv
n of 25%of 25
ction ofction o
eductioneduct
ReducRedof Use
Change ihange
study study
!!C
pepeofof
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 14of 106Pharmacokinetic Endpoints
!To determine the plasma concentrations of TAK-935 and the TAK-935 metabolite (M-I) at 
multiple time points
!Estimate exposure parameters from sparse PK samples using population modelling
!Determine any potential relationship with estimated TAK-935 exposure parameters with 
changes in seizure frequency
Safety Endpoints
!Incidence of treatment-emergent adverse events (TEAEs)
!Change in behavioral and adaptive functional measures using the VABS
!Change in behavior measures using total scores and subscale scores of ABC-C for patients 
â‰¥6 years of age
!Incidence of abnormal values for clinical laboratory evaluations, vital signs, body weight and 
height, and electrocardiogram (ECG) parameters after TAK-935 treatment
!Change from Baseline in clinical laboratory evaluations, vital signs, body weight, C-SSRS, and 
ECG parameter values after TAK-935 treatment
!Mean percent of myoclonic- and atypical-absen ce free days in patients receiving TAK-935 as 
compared to placebo during the Maintenance Period
Safety :
An iDMC will monitor the patient safety in accordance with the iDMC charter.
Statistical Considerations:All statistical analyses will be performed using SAS
Â®Version 9.4 or higher. All clinical study data will 
be presented in patient data listings. Data summaries will be presented for all endpoints and will include 
descriptive statistics (number of patients [n], mean, standard deviation [SD], first quartile [Q1], median, third quartile [Q3], minimum and maximum) for continuous variables, and frequency and percentage for categorical and ordinal variables. If there are missing values, the number of missing will be presented, 
but without a percentage.
For all analyses, â€˜Baselineâ€™ refers to the prospective 4-week Baseline Period. Modified Intent-to-Treat Analysis Set
All randomized patients who have received at least 1 dose of study drug and have been assessed for at 
least 1 day in the Treatment Period will be included in th e modified intent-to-treat (mITT) analysis set. 
All mITT analyses will be based on each patientâ€™s randomized treatment assignment.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee (Me (M --I) aI
modellingodellin
re parame param
es using s using 
nd subscd sub
aboratoraborato
arameterramete
aboratoryborato
K-935 tr935 
and atyand a
ing the Mng theof
the patithe pmm
derationeratio
l analyseanaly
ed in pad in p
tive statiive sta
d quartilequarti
ategoricategori
but witbut w
FoFoNo
pepems of
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 15of 106Efficacy Analysis Set
All mITT patients whose efficacy assessments are compliant with Protocol Amendment 2 will be 
included in the efficacy analysis set. Efficacy analyses for primary and secondary efficacy endpoints will 
be based on the efficacy analysis set.  
Efficacy analyses will be based on each patientâ€™s randomized treatment 
assignment.
Safety Analysis Set
All randomized patients who take at least 1 dose of study medication will be included in the Safety 
Analysis Set. Safety analyses will be based on the medication that was actually administered to each 
patient. 
Stratification by Seizure Type
At Visit 2, all eligible patients will be stratified by 2 categories: Dravet syndrome patients with 
convulsive seizures, and LGS patients with drop seizures to ensure balance of treatments within each 
stratum. Note that patients with the minimum number of convulsive or drop seizures will be assigned to 
a stratum following the stratification rules.
Patients with Dravet syndrome :
!46 eligible patients diagnosed with Dravet syndrome with â‰¥3 convulsive seizures per 28 days 
during the prospective Baseline period will be randomized into the Dravet syndrome stratum.
Patients with LGS (Lennox Gastaut Syndrome):
!80 eligible patients diagnosed with LGS with â‰¥4 drop seizures per 28 days during the 
prospective Baseline period will be randomized into the LGS stratum.
If a patient does not meet any of these criteria, the patient will be considered a screen failure.
Primary Efficacy Analyses
For the patients randomized to the Dravet syndrome stratum ( â‰¥3 convulsive seizures per 28 days), 
convulsive seizure frequencies per 28 days for the 4-week prospective Baseline Period and the
Maintenance Period will be calculated.
For the patients randomized to the LGS stratum ( â‰¥4 drop seizures per 28 days), drop seizure frequencies 
per 28 days for the 4-week prospective Baseline Period and the Maintenance Period will be calculated.
For each patient, percent change from Baseline to the frequency during Maintenance Period (per 
28 days) will be calculated for the seizure type corresponding to the assigned stratum of that patient (convulsive for the Dravet stratum and drop for the LGS stratum). Percent change from Baseline will be 
compared between TAK-935 and placebo using a Mann-Whitney (Wilcoxon) test adjusting for Baseline 
and randomization stratum.
The null hypothesis of no treatment difference will be tested at a two-sided 0.05 level of significance. 
The Mann-Whitney estimator and the corresponding 95% confidence interval (CI) comparing TAK-935 
with placebo will also be displayed.
Secondary Efficacy Analyses
For each patient, percent change from Baseline to the frequency during Treatment Period (per 28 days) 
will be calculated for the seizure type corresponding to the assigned stratum of that patient (convulsive 
for the Dravet stratum and drop for the LGS stratum). Percent change from Baseline will be compared between TAK-935 and placebo using a Mann-Whitney (Wilcoxon) test adjusting for Baseline and randomization stratum.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms ofety ety 
to each o each
patientsatient
reatmenatme
seizuresseizure
h hâ‰¥3 conâ‰¥3 co
mized intized in
â‰¥4 dropâ‰¥4 dro
mized inmized in
, the patithe pa
avet synvet sy
28 days28 day
ulated.lated
d to the Lto the
ek prospk pros
cent chacent ch
calculatelcula
r the Drathe D
etween Tetween
omizatiomizati
null hypnull hy
he Manne Man
with plwith p
SecSpepeof Useofof
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 16of 106For Dravet syndrome stratum, percent change in convulsive seizure frequency from Baseline to the 
frequency of convulsive seizures during the Maintenance Period will be compared between TAK-935 
and placebo using a Mann-Whitney test adjusting for Baseline convulsive seizure frequency and 
randomization stratum. For the drop seizures in LGS stratum, percent change in drop seizure frequency from Baseline to the frequency of drop seizures during the Maintenance Period will be compared between TAK-935 and placebo using a Mann-Whitney test adjusting for Baseline drop seizure 
frequency. For the 2 randomization strata, the null hypothesis of no treatment difference will be tested at 
a two-sided 0.1 level of significance. The Mann-Whitney estimator and the corresponding 95% confidence interval (CI) comparing TAK-935 with placebo will also be displayed.
The primary analysis will be repeated for the 20-week Treatment Period.
For the Dravet syndrome stratum, the proportion of treatment responders based on â‰¥25% worsening, 
<25% and >1% worsening, no change (Worsening of 1% to Reduction of 1%), â‰¥25% reduction, â‰¥50% 
reduction, â‰¥75% reduction, and 100% reduction from Baseline in convulsive seizure frequency for the 
Maintenance Period will be summarized for TAK-935 and placebo. The 95% CIs for the difference of 
proportions will be displayed for each responder category. For the LGS stratum, the proportion of treatment responders based on â‰¥25% worsening, <25% and >1% worsening, no change (Worsening of 
1% to Reduction of 1%), â‰¥25% reduction, â‰¥50% reduction, â‰¥75% reduction, and 100% reduction from 
Baseline in drop seizure frequency for the Maintenance Period will be summarized for TAK-935 and placebo; 95% CIs for the difference of proportions will be displayed for each responder category.
Change in CGI-S/C responses of Investigator reported impression of efficacy and tolerability of study 
drug and change in Care GI-C responses of parent/family reported impression of efficacy and tolerability of study drug will be analyzed descriptively.
Techniques for handling missing information with respect to reporting of seizures in the treatment period 
(Dose Optimization and Maintenance) will be specified in detail in the statistical analysis plan (SAP). 
Safety Analyses
Descriptive statistics will be used to summarize all safety endpoints, by treatment group. Two-sided 95% 
CIs will be presented where meaningful. Data summaries will be displayed for incidence of AEs, clinical 
laboratory variables, vital signs, body weight and height, ECG parameters, percent myoclonic and atypical absence-free days, as well as changes in behavioral and adaptive functioning measures using 
VABS and sub-scales of ABC-C, as appropriate. 
Pharmacokinetic Analyses
Plasma concentrations of TAK-935 and the metabolite of TAK-935 (M-I) will be summarized and 
displayed graphically per nominal time points. Mean plasma concentrations over time will be presented 
graphically.
The plasma concentration-time and PD (24HC) data obtained in this study will be used to estimate TAK-CCI
PropertypepeCommercial Use Only and Subject to the Applicable Terms ofat 
worsenworse
reductioreduct
re frequefrequ
s for the for th
um, the pm, the
ng, no ch, no c
ction, antion, a
e summsumm
ed for ead for e
sion of ion of
eported ported
espect tospec
ecified icified
mmarize marize
ful. Dataul. Dat
ody weigdy wei
well as chll as 
C-C, as C, asof Useofof
perty of Takeda: For Non-Co
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 17of 106935 exposure parameters, analyze target engagement in terms of 24HC reduction, and evaluate potential 
relationships between TAK -935 exposure or 24HC responses and clinical and safety endpoints. Full 
details of the relevant population PK/PD modeling work (including objectives, relevant endpoints, 
methodology, software, etc.) will be defined in a separate data a nalysis plan or the study SAP , and 
results will be reported separately. The actual elapsed time from dose will be used in the final PK 
modeling and parameter calculations.
Sample Size Justification:
The sample size calculations are based on unadjusted Man n-Whitney (Wilcoxon rank -sum) test.
The randomization will be stratified by 2 categories: Dravet syndrome stratum and LGS stratum. The 
primary endpoint is defined as percent change in convulsive seizures for the patients in the Dravet 
syndrome and percent change in drop seizures for those in the LGS stratum.
Assuming that the mean difference in percentage change from baseline between active and placebo arms 
is 29% for the 2 strata combined and the standard deviation is 42.3%, with 56 patients per treatment 
group, there will be 92% power to test the treatment difference at a two -sided 0.05 level of significance. 
Assuming a 10% drop -out rate, 63 patients per arm will be randomized.
Within the 2 randomization strata, hypothesis tests will be performed at levels of significance higher 
than 0.05 in this Phase 2 proof of concept trial and will have power of 80%. The following table shows 
the within stratum sample size calculations:
Dravet Syndrome Stratum LGS Stratum
Alpha 0.1 0.1
1-sided or 2 -sided 2 2
Treatment Difference 0.30 0.28
Standard Deviation 0.35 0.45
Power 80% 80%
N per group 20 36
N per group (after 10% adjustment) 23 40
Total N 46 80
Interim Analysis:
Plasma concentrations of TAK -935 in first 12 patients within each category of aged â‰¥9years and 
<9years will be used to estimate PK parameters using the current population PK model. If needed, 
adjustment to the dose will be made. The frequency of PK sample collection may be changed based on 
results of interim analysis.
Overall and by -stratum (LGS and Dravet strata) futility and interim analyses may be performed. 
Enrollment may be stopped for one of the strata if the treatment effect is not sufficiently strong. If one 
stratum is discontinued, enrollment will continue with the other stratum until the total sample size is 
achieved. Thresholds for stopping enrollment will be pre -specified in the interim analysis plan .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 18of 106TABLE OF CONTENTS
SPONSOR SIGNATURE PAGE ................................................................................................2
PROTOCOL AMENDMENT 2 SUMMARY OF CHANGES ....................................................3
INVESTIGATORâ€™S AGREEMENT ...........................................................................................4
1. SYNOPSIS ..........................................................................................................................5
TABLE OF CONTENTS .......................................................................................................... 18
LIST OF TABLES .................................................................................................................... 22
LIST OF FIGURES .................................................................................................................. 22
2. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ...................................... 23
3. INTRODUCTION ............................................................................................................. 25
3.1. Background ................................................................................................................. 25
3.2. Study  Rati onale ........................................................................................................... 25
4. STUDY OBJECTIVES AND ENDPOINTS ...................................................................... 27
4.1. Object ives................................................................................................................... 27
4.1.1. Primary Object ive................................
................................................................ 27
4.1.2. Secondary  Object ives........................................................................................... 27
4.1.3. Exploratory  Objectives ......................................................................................... 28
4.1.4. S afety Objectives .................................................................................................28
4.2. Endpoints .................................................................................................................... 29
4.2.1. Primary Endpo int.................................................................................................29
4.2.2. Seconda ry Efficacy  Endpoints .............................................................................. 29
4.2.3. Exploratory  Endpo ints......................................................................................... 30
4.2.4. Pharmacokinet ic Endpo ints.................................................................................. 30
4.2.5. Safety Endpo ints.................................................................................................. 30
5. INVESTIGATI ONAL PLAN ............................................................................................ 31
5.1. Summary  of Study  Design .......................................................................................... 31
5.1.1. End of Study  Definit ion....................................................................................... 32
5.1.2. S tudy Extensio n................................................................................................... 32
5.2. Selection and Timing o f Doses in the Study ................................................................ 33
5.2.1. Modeling and Simulat ion of Clinical Data ........................................................... 33
6. STUDY POPULATION .................................................................................................... 34
6.1. Inclusio n Cri teria........................................................................................................ 34
6.2. Exclusio n Cri teria....................................................................................................... 36
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 19of 1066.3. Discontinuati ons ......................................................................................................... 37
6.3.1. Discontin uation of  Patients.................................................................................. 37
6.3.2. Discontinuati on of  Study  Sites/Si te Terminated by  Sponsor .................................39
6.3.3. Discontinuati on of  the Study /Study  Terminated by Sponsor .................................39
7. TREATMENT ................................................................................................................... 40
7.1. Materi als and Supplie s................................................................................................ 40
7.1.1. Storage ................................................................................................................. 40
7.2. Treatments Administered ............................................................................................ 40
7.3. Metho d of Assignment to Treatment ........................................................................... 42
7.4. Continued Access to Study  drug .................................................................................. 43
7.5. Blinding ...................................................................................................................... 43
7.6. Concomitant Medications and Non -Pharmaco logic Therapies and Procedures ............ 44
7.7. Treatment Compliance ................................................................................................ 44
8. STUDY ASSESSMENTS .................................................................................................. 45
8.1. Study  Procedures ........................................................................................................ 45
8.1.1. Inform ed Consent Procedure ................................................................................ 45
8.1.1.1. Study  Inform ed Consent Procedure ............................................................... 45
8.1.2. Dem ographics, Medi cal History , and Medicat ion History  Procedure .................... 45
8.1.3. Physical Examinat ion Procedure .......................................................................... 45
8.1.4. Neurol ogical Examinat ion Procedure ................................................................... 46
8.1.5. Weight and Height ............................................................................................... 46
8.1.6. Vital Signs Procedure ........................................................................................... 46
8.1.7. Seizure Diary  Procedure ....................................................................................... 46
8.1.8. Docum entati on of  Study  Drug .............................................................................. 47
8.1.9. Docum entati on of  Conco mitant Medi cations........................................................ 47
8.1.10. Docum entati on of  Concurrent Medi cal Condit ions............................................... 47
8.1.11. Procedures for Clinical Laboratory  Samples ......................................................... 47
8.1.12. Contraception and Pregnancy Avo idance Procedure ............................................. 48
8.1.13. ECG Procedure .................................................................................................... 49
8.1.14. Clinical Assessment of Suicidal Ideat ion and Behavior ........................................ 49
8.1.15. Aberrant Behavior Checklist ................................................................................ 49
8.1.16. Vineland Adapt ive Behavior Scale ....................................................................... 50
8.1.17. Qualit y of Life in Childhood Epilepsy .................................................................. 50
8.1.18. Sleep Disruption Numerical Rat ing Scale ............................................................. 50
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 20of 1068.1.19. Caregiver Glo bal Impressio n of Change (Care GI -C)........................................... 50
8.1.20. Clinicianâ€™s Clinical Glo bal Impressio n of Severit y and Change (CGI -S/C) .......... 51
8.1.21. Early Terminat ion................................................................................................ 51
8.1.22. Pharmacokinet ic Sample Co llection and Analysis ................................................ 51
8.1.22.1. Collect ion of Plasma Samples for TAK- 935 and M -I PK Evaluat ion............. 51
8.1.22.2. Bioanaly tical Methods for TAK -935 and M -I............................................... 52
8.1.22.3. Pharma cokinet ic Parameters ......................................................................... 52
8.1.23. Pharmacodynamic Sample Co llection and Analysis ............................................. 52
8.1.23.1. Collect ion of Plasma Samples for Pharmacodynamic Evaluat ion.................. 52
8.1.23.2. Bioanaly tical Methods for 24HC ................................................................... 53
8.1.23.3. Pharmacodynamic Parameters ....................................................................... 53
8.1.23.4. Docum entati on of  Screen Failure .................................................................. 53
8.1.23.5. Docum entati on of  Study  Entrance .................................................................53
8.2. Sample Collect ion and Test ing.................................................................................... 54
8.2.1. Optional Blood Sam ples f or Storage: Potential Exploratory  Research .................. 54
8.3. Safety Evaluat ions...................................................................................................... 54
8.3.1. Adverse Events .................................................................................................... 54
8.3.1.1. Severit y Assessment ..................................................................................... 56
8.3.1.2. Causalit y Assessment .................................................................................... 56
8.3.1.3. Serious Adverse Events ................................................................................ 56
8.3.1.4. Suspected Unexpected Serious Adverse React ions........................................ 57
8.3.1.5. Reporting Adverse Events ............................................................................. 58
8.3.1.6. Sponsor Reporting Requirements .................................................................. 58
8.3.1.7. Invest igator Reporting Requirements ............................................................ 58
8.3.2. Exposure During Pregnancy and/or Lactation ...................................................... 59
8.3.3. Safety Moni toring ................................................................................................ 59
8.3.3.1. Repor ting of Abnormal Liver Function Tests ................................................ 59
8.4. Appropriateness of Measurements ............................................................................... 60
9. DAT A QUALITY ASSURANCE ...................................................................................... 61
9.1. Data Co llection and Storage ........................................................................................ 61
10. STATISTICAL METHODS AND PLANNED ANALYSES ............................................. 63
10.1. General Considerations ............................................................................................ 63
10.2. Stratificat ion by Seizure Ty pe.................................................................................. 63
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 21of 10610.3. Determinat ion of Sample Size ................................................................................. 63
10.4. Analysis Sets ........................................................................................................... 64
10.4.1. Modified Intent -to-Treat Analysis Set .................................................................. 64
10.4.2. Efficacy Analysis Set ........................................................................................... 64
10.4.3. Safety Analysis Set .............................................................................................. 65
10.5. Dem ographics and Baseline Characterist ics............................................................. 65
10.6. Patient Disposi tion.................................................................................................. 65
10.7. Concomitant Medications and Non -Pharmaco logic Therapies and Procedures ......... 65
10.8. Treatment Compliance ............................................................................................. 65
10.9. Efficacy Analyses .................................................................................................... 66
10.9.1. Primar y Efficacy  Analyses ................................................................................... 66
10.9.2. Secondary  Efficacy  Analyses ............................................................................... 66
10.9.3. Exploratory  Analysis ............................................................................................ 67
10.10. Safety Analyses ....................................................................................................... 67
10.10.1. Physical Examinat ion, Vi tal Signs, and Other Physical Findings ...................... 67
10.10.2. Clinical Laboratory  Tests ................................................................................. 68
10.10.3. Adverse Events .................................................................................................68
10.11. Pharmac okinet ic/Pharmacodynamic Analyses ......................................................... 68
10.12. Other Statist ical Issues ............................................................................................. 68
10.12.1. Significance Levels .......................................................................................... 68
10.12.2. M issing or Invalid Data .................................................................................... 68
10.13. Interim Analyses ..................................................................................................... 69
11. INFORMED CONSENT, ETHICAL REVIEW, AND REGULATORY 
CONSIDERATIONS ................................................................................................................ 70
11.1. Inform ed Consent .................................................................................................... 70
11.2. Data Monit oring Committee .................................................................................... 70
11.3. Ethical Review ........................................................................................................ 70
11.4. Regulatory  Considerat ions....................................................................................... 71
11.4.1 .Confident iality..................................................................................................... 71
11.4.2. Invest igator Informat ion....................................................................................... 72
11.4.3. Protocol  Signatures .............................................................................................. 72
11.4.4. Final Report Signature ......................................................................................... 72
11.5. Publicat ion Policy.................................................................................................... 72
12. LIST OF REFERENCES ................................................................................................... 73
Appendix 1. Schedule of Assessments ..................................................................................... 75
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 22of 106Appendix 2.STUDY TAK -935- 2002 (OV935): CLINICAL LABORATORY TESTS ............ 79
Appendix 3.STUDY TAK -
935-2002 (OV935): SAMPLING SUMMARY ............................. 80
Appendix 4.STRONG CYP3A4 INDUCERS AND INHIBITORS ......................................... 81
Appendix 5.
OVERVIEW OF MAJOR CHANGES IMPLEMENTED BY AMENDMENTs ..82
LIST OF TABLES
Table 1 Dosing Schedule by  Wei ght...................................................................................... 41
Table 2 Within-Stratum  Sam ple Size Calculat ions.................................................................64
Table 3 Schedule of Assessments .......................................................................................... 76
LIST OF FIGURES
Figure 1:Study  Design for Clinical Protocol OV/TAK -935- 2002 (OV935) .............................. 32
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 23of 1062. LIST OF ABBREVIATION S AND DEFINITIONS OF TERMS
Term Definition
24HC 24S-hydroxycholesterol
AED antiepileptic drugs
APP/PS -1 dTg amyloid precursor protein and presenilin -1 double transgenic
AUC area under the plasma concentration -time curve
AUC 24 area under the plasma concentration -time curve from time 0 to 24 hours
AUC 24,ss area under the plasma concentration -time curve from time 0 to 24 hours at steady state
AUC Ï„ area under the plasma concentration -time curve during a dosing interval
BID twice daily
CGI-S/C Clinicianâ€™s Clinical Global Impression of Severity and Change
Care GI-C Caregiver Global Impression of Change
CH24H cholesterol 24 Shydroxy lase
Cmax maximum observed plasma concentration
Cmax.ss maximum observed plasma concentration during a dosing interval, at steady state
CNS central nervous system
C-SSRS Columbia â€“Suicide Severity Rating Scale
CYP cytochrome P -450
DEE developmental and epileptic encephalopathy
DRF dose range â€“finding
DS Dravet syndrome
ED 50 median effective dose
EE epileptic encephalopathy
EEG Electroencephalogram
EO enzyme occupancy
FDA Food and Drug Administration
GABA Î³-amino butyric acid
GABAA Î³-amino butyric acid subunit A
HIE hypoxic -ischemic -encephalopathy
I steady state total Cmax at the highest dose of the inhibitor
IB Investigatorâ€™s Brochure .
IC50 50% inhibitory concentration
iDMC independent Data Monitoring Committee
ILAE International League Against Epilepsy
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 24of 106Term Definition
IND Investigational New Drug
IS infantile spasms
KCl potassium chloride
KO Knockout
LGS Lennox -Gastaut syndrome
M-I N-oxide metabolite of TAK -935
NMDA N-methy l-D-aspartate
OLE open -label extension
PET positron emission tomography
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PO Oral
QD once daily
SRS spontaneous recurrent seizures
t1/2z terminal disposition phase half -life
tmax time of first occurrence of Cmax
TMEV Theilerâ€™s murine encephalomyelitis virus
TSC tuberous sclerosis complex
UGT uridine diphosphate glucuronosyltransferase
VNS vagal nerve stimulator
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 25of 1063. INTRODUCTION
3.1. Background
More information about the known and expected benefits, risks, and reasonably anticipated 
adverse events (AEs) of TAK- 935 may be found in the current edition of the Investigatorâ€™s 
Brochure (IB).
3.2. Study Rationale
Epileptic encephalopathies (EE) are a group of rare disorders in which the unremitting epileptic activity contributes to severe cognitive and behavioral impairment and these can worsen 
overtime leading to progressive cerebral dysfunction .
4Epileptic encephalopathies start at an early 
age and manifest with seizures, which are usually intractable, have aggressive 
electroencephalogram (EEG) paroxysmal abnormaliti es, and severe neurocognitive deficits. 
Potential to halt or improve the neurocognitive consequences of epilepsy with a successful CCI
Property of Takeda: Fomatatioion an
events (Aents (
ure (IB)ure (IB
3.2.2.
EpilEpif Use
For Non-Commercial Use Only and Subject to the Applicable Terms of U
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 26of 106treatment is a fundamental concept behind clustering of these disorders. In a group of severe 
genetic disorders causing EE, the underlying genetic mutation also contributes to developmental 
delay, in addition to severe epilepsy in these patients. Hence, the International League Against
Epilepsy (ILAE) expanded the concept of EE from the severe epilepsies with onset in infancy and childhood to epilepsy syndromes associated with  encephalopathy including those that have a 
genetic etiology .
5The revised classification now refers to DEEs. Dravet syndrome (DS) or severe 
myoclonic epilepsy in infancy is one of th e most well-known disorders of the epileptic 
encephalopathies. Clinically, DS is characterized by frequent convulsive febrile seizures, 
followed later by nonfebrile seizures, mainly cl onic and unilateral, of long duration and frequent 
status epilepticus (SE). Lennox Gastaut syndrome (LGS) is rare and is one of the most severe forms of childhood epilepsy. The syndrome usually has its onset between the ages of 1 and 
8 years (typically between 3 and 5 years), but occasionally it occurs in children who are more 
than 8 years old, even into adulthood. The hallmarks of the disease include: presence of multiple seizure types: the hallmark tonic-atonic seizures; the most hazardous are drop seizures/attacks, 
which can lead to serious injuries and occur in about 56% of patients. Other seizure types include 
atypical absences, but tonic-clonic, myoclonic, a nd partial seizures are al so frequently present.
The current study is designed to further characterize the effects of TAK-935 on seizure 
frequency using a seizure diary. An additional aim is to explore the safety, tolerability, PK, and PD of multiple-dose TAK-935 administration in pediatric patients with developmental and/or 
epileptic encephalopathies.CCI
Property of Takeda: For Non-Commercial Use Oharacteraract
diititiiionalon
nisistratitratto the Applicable Terms of Usee 
frequenfreque
st severseve
of 1 anof 1 a
who arwho a
presencresen
drop seiop se
Other seOther
are alre alsos
e Only and Subject to
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 27of 1064. STUDY OBJECTIVES AND ENDPOINTS
Study  objectives and associated endpo ints are presented in Secti on 4.1and Secti on 4.2, 
respectively; the frequency and timing of study  measurements is pr ovided in the Schedule of 
Assessments ( Table 3). Informati on regarding sample collect ion and safet y data collect ion are 
presented in Secti on
 8.
4.1. Objectives
4.1.1. Primary Objective
The primary  object ive of this study  is to invest igate the effect on the frequency o f all seizures 
(convulsive and drop) in pa tients treated with TAK -935 as an adjunct ive therapy co mpared to 
placebo in the Maintenance Period.
4.1.2.
Secondary Objectives
ï‚·To investigate the effect on the frequency o f all seizures (convulsive and drop) in 
patients treated with TAK -935 as an adjunct ive therapy compared to placebo 
throughout the Treatment Period
ï‚·To investigate the effect on the frequency o f convulsive seizure in patients with 
Dravet Syndro me treated with TAK -935 as an adj unctive therapy co mpared to 
placebo in the Maintenance Period
ï‚·To investigate the effect on the frequency o f drop sei zure in pat ients with LGS treated 
with TAK -935 as an adj unctive therapy co mpared to pl acebo in the Maintenance
Period
ï‚·To investigate the seizure frequency  of LGS pati ents consi dered treatm ent responders 
throughout the Maintenance Period; treatment responders are defined as those with:
ï€­Worsening of 25% or more in drop seizures fro m baseline
ï€­Worsening of 1% to 25% in drop seizures fro m baseline
ï€­No change in drop seizures from baseline ( Worsening of 1% to Reduction of 1%)
ï€­Reduction o f 25% or more in drop seizures from baseline
ï€­Reduction o f 50% or more in drop seizures from baseline
ï€­Reduction of  75% or m ore in drop sei zures from baseline
ï€­Reduction o f 100% in drop seizures from baseline
ï‚·To investigate the seizure frequency  of Dravet patients considered treatment 
responders throughout the Maintenance Period; treatm ent responders are defined as 
those wi th:
ï€­Worsening of 25% or more in convulsive seizures fro m baseline
ï€­Worsening of 1% to 25% in convulsive seizures from baseline
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 28of 106âˆ€No change in convulsive seizures from baseline (Worsening of 1% to Reduction 
of 1%)
âˆ€Reduction of 25% or more in convulsive seizures from baseline
âˆ€Reduction of 50% or more in convulsive seizures from baseline
âˆ€Reduction of 75% or more in convulsive seizures from baseline
âˆ€Reduction of 100% in convulsive seizures from baseline
!To investigate the change in Clinical Global Impression of Severity and Change 
assessment (CGI-S/C) responses of Investigator and Caregiver Clinical Global Impression of Change (Care GI-C) in patients treated with TAK-935 as an adjunctive 
therapy compared to placebo
!To characterize the relationship between plasma 24HC levels and seizure frequency
4.1.3. Exploratory Objectives
4.1.4. Safety Objectives
!To evaluate safety and tolerability of TAK-935 as adjunctive therapy as compared to 
placebo
!To investigate the effect on behavior and adaptive function in patients treated with 
TAK-935 as adjunctive therapy compared to placebo using the Vineland Adaptive Behavioral scales (VABS) and Aberrant Behavior Checklist-Community questionnaire (ABC-C)
!To evaluate the occurrence of myoclonic and atypical absence-free days to determine 
if there is worsening of these seiz ure types during treatment with TAK-935CCI
Property of Takeda: For Non-Comctivestives
uate safeate sa
booto the Applicable Terms of Useange nge 
GloGlobal ba
as an ads an a
and seizd seiz
To invesTo inve
TAKTAK
BeBommercial Use Only and Subject to 
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 29of 1064.2. Endpoints
4.2.1. Primary Endpoint
The primary  endpoint for thi s study  is the percent change from Baseline in seizure frequency  per
28 day s (based only on convulsive seizures for the patients in the Dravet syndrome stratum and 
drop sei zures for the patients in the LGS stratum) in patients receiving TAK -935 as com pared to 
placebo during the Maintenance Period.
4.2.2. Secondary Efficacy Endpoin ts
ï‚·Percent change fro m Baseline in seizure frequency per 28 day s (based only on 
convulsive seizures for the patients in the Dravet syndro me stratum and drop seizures 
for the patients in the LGS stratum) in pat ients receiving TAK -935 as com pared to 
placebo during the Treatment Period
ï‚·Percent change fro m Baseline in convulsive seizure frequency  per 28 day s in patients 
rando mized to the Dravet syndro me stratum and receiving TAK -935 as com pared to 
placebo during the Maintenance Period
ï‚·Percent change fro m Baseli ne in drop sei zure frequency per 28 day s in pat ients 
rando mized to the LGS stratum and receiving TAK -935 as com pared to pl acebo 
during the Maintenance Period
ï‚·Proporti on of  patients in the LGS stratum considered treatment responders throughout 
the Maintenance Peri od; treatm ent responders defined as those with: 
-Worsening of 25% or m ore in drop sei zures fro m baseline
-Worsening of 1% to 25% in drop seizures fro m baseline
-No change in drop seizures fro m baseline (Worsening of 1% to Reduction of 1%)
-Reduction o f25% or more in drop seizures fro m baseline
-Reduction o f 50% or more in drop seizures fro m baseline
-Reduction o f 75% or more in drop seizures fro m baseline
-Reduction o f 100% in drop seizures from baseline
ï‚·Proporti on of  patients in the Dravet syndro me strat um considered treatment responders 
throughout the Maintenance Period; treatment responders are defined as those with: 
-Worsening of 25% or m ore in convulsive seizures fro m baseline
-Worsening of 1% to 25% in convulsive seizures from baseline
-No change in co nvulsive seizures fro m baseline (Worsening of 1% to Reduction 
of 1%)
-Reduction o f 25% or more in convulsive seizures from baseline
-Reduction o f 50% or more in convulsive seizures from baseline
-Reduction o f 75% or more in convulsive seizures from baseline
- R educti on of  100% in convulsive seizures from baseline
ï‚·Change in CGI -S/C responses of Invest igator reported impressio n of efficacy and 
tolerabilit y of study  drug
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 30of 106!Change in Care GI-C responses of parent/family reported impression of efficacy and 
tolerability o f study drug
!To characterize plasma 24HC levels and change in seizure frequency in patients 
treated with TAK-935 as an adjunctive therapy
4.2.4. Pharmacokinetic Endpoints
!To determine the plasma concentr ations of TAK-935 and the TAK-935 metabolite 
(M-I) at multiple time points
!Estimate exposure parameters from sparse PK samples using population modelling 
!Determine any potential relationship with estimated TAK-935 exposure parameters 
with changes in seizure frequency 
4.2.5. Safety Endpoints
!Incidence of treatment- emergent adverse events (TEAEs)
!Change in behavioral and adaptive functional measures using the VABS
!Change in behavior measures using total scores and subscale scores of ABC-C for 
patients â‰¥6 years of age
!Incidence of abnormal values for clinical laboratory evaluations, vital signs, body 
weight and height, and electrocardiogram (ECG) parameters after TAK-935 treatment
!Change from Baseline in clinical laboratory  evaluations, vital signs, body weight, 
Columbiaâ€“Suicide Severity Rating Scale (C-SSRS), and ECG parameter values after 
TAK-935 treatment
!Mean percent of myoclonic- and atypical-absence free days in patients receiving
TAK-935 as compared to placebo during the Maintenance PeriodCCI
Property of Takeda: For Non-Commercial Use Only and SubjecfT A K -TAK- 9
sparse Psparse 
nship wnship
uency uency 
mentent--eme
avioral viora
behavibehav
â‰¥6 yâ‰¥6 yea
cidence dence
weiweiUse
gghth
!ChaC
Cect to the Applicable Terms of Us
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 31of 1065. INVESTIGATIONAL PLAN
5.1. Summary of Study Design
Study  TAK -935-2002 (OV935) is a Phase 2, mult icenter, randomized, double -blind, placebo -
controlled, parallel -group, study  in pediatri c patients (aged â‰¥2 and â‰¤17 y ears) wi th Dravet 
syndro me and LGS demonstrating 
â‰¥3 convulsive or â‰¥4 drop seizures , respect ively, per m onth 
during the 3 months immediately  prior to Screening (based on histori cal information) and 
â‰¥3convulsive or â‰¥4 drop seizures , respect ively, during a minimum of 4 weeks during the 
prospective Baseline Period (based on the seizure diary  records). Convulsive seizures includ e 
generalized tonic -clonic, focal to bilateral  tonic -cloni c with impai red awareness, hemi -clonic and 
simultaneous bilateral clo nic (generalized clo nic) seizures. Drop seizures are defined as 
involving the ent ire body , trunk, or head that leads to a fall, i njury, sl umping in a chair, or head 
hitting a surface, or that could have led to a fall or injury, depending on the position of the 
patient at the time of the seizure or spell. Examples of seizures causing drop include, but are not 
limited to, atonic, clon ic, and toni c seizures.
Approximately  126 pati ents will be rando mized to ensure 112 evaluable patients. Randomization 
will be stratified by 2 categories: Dravet syndro me patients wi th convulsive seizures and LGS 
patients wi th drop sei zures. Stratificat ion will be performed to ensure balance of treatments 
within each stratum.
The study  will begin wi th a phased enro llment based on age. Patients aged â‰¥9 years will  be 
enrolled first, prior to open enrollment in the study, for assessment of safet y. The independe nt 
Data Monitoring Committee (iDMC) will review the adverse event (AE) profile sof the fi rst
12patients aged â‰¥9 years com pleting 4 weeks of treatment across all ongoing pediatric TAK -935 
studi es, prior to recommending treatment for patients aged <9 years.
This study  consists of 2 m ain periods:
ï‚·4-to 6-week Screening/Baseline Period
ï‚·20-week Treatment Period
-8-week Dose Optimizat ion Period
-12-week Maintenance Period
The Treatm ent Peri od consists of the Dose Optimization Period and Maintenance Period. 
Figure 1illustrates the study  design.
Dravet syndrome patients who have had, on average, â‰¥3 convulsive or LGS patients who have 
had on average â‰¥4 drop sei zures per m onth during the 3 months immediately  prior to Screening 
(based on historical informat ion) and â‰¥3 convulsive or â‰¥4 drop seizures , respectively, during a 
minimum o f 4weeks during the Baseline Period (based on the seizure diary  records) will be 
eligible for entry  into the study .
At the end of the prospective 4 -to 6-week Screening/ Baseline Peri od, pati ents will  return to the 
clinic (Visit 2). Seizure diaries will be reviewed by the Medical Monitor or del egated staff and if 
a pati ent di d not m eet the eligibilit y criteria, including minimum number of seizures requi red for 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK- 935-2002 (OV935) Amendment 2 OvidTherapeu tics, Inc.
Date: 11February  2019 
Page 32of 106the study  and seizure stratum, the patient will be discontinued from the study  and considered a 
screen failure.
Figure 1: Study Design for Clini cal Protocol OV/TAK -935-2002 (OV935)
Patients and/or pati entsâ€™ caregivers will be provided with a seizure diary  and will be instructed to 
record sei zure data daily  starti ng at Visit 1 (screening visit) and to continue throughout the study . 
The seizure d iary data will be collected during the prospective Baseline Period and will be used 
as the baseline seizure data for endpoint analyses. An external independent or Sponsorâ€™s 
reviewer(s) will confirm the pat ientâ€™s diagnosis prior to randomization.
Patients w ho cannot tolerate Dose 1 will be withdrawn fro m the study .
5.1.1. End of Study Definition
The end o f the study  for an individual pat ient is defined as the l ast protocol -specified contact 
with that pati ent. The overall end of the study  is defined as the l ast prot ocol-specified contact 
with the l ast pati ent ongoing in the study .
5.1.2. Study Extension
Following com pletion of the study , pati ents will have the option to enroll in a long -term,
open -label extensio n (OLE) study  (under a separate protocol, TAK -935-18-001[OV935 ]). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 33of 1065.2. Selection and Timing of Doses in the Study
Preclinical data from rodent epilepsy models s uggest potentially efficacious exposures, and 
safety data from nonclinical studies were used to determine exposure-based safety margins. 
Clinical safety and tolerability d ata from single- and multiple-dose Phase 1 studies in adult 
healthy volunteers were used to pe rform PK, PD, and enzyme occupancy (EO) analyses with 
allometric scaling to determine an appropriate dose of TAK-935 for pediatric patients.
5.2.1. Modeling and Simulation of Clinical Data
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usekeda: For Non-Commercial Use Only and Subject to the Applicable Ter
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 34of 1066. STUDY POPULATION
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
re-screened. Refer to Section 8.1.23.4 for addi tional informat ion on recording screen failures.
Individuals may  be re-screened up to 2 times, after consultation with the Medical Moni tor. 
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  the f ollowing cri teria and 
none of the exclusio n criteria:
1.The patient and patientâ€™s legal representative (i .e., parent or legal guardian )are willing 
and able to read, understand, and sign the informed consent form and assent, if applicable
2.Male and female patie nts aged â‰¥2 and â‰¤17 y ears at the time of informed consent and the
first dose of study  drug
3.Clinical diagnosis of LGS and a history  of, on average, â‰¥4 drop seizures per month 
during the 3 months immediately  prior to Screening based on historical informat ion, and 
the pati ent has â‰¥4 drop sei zures during a minimum of 4 weeks of seizure data collect ion 
during the prospective Baseline Period
-OR-
Clinical diagnosis of Dravet syndro me and a history o f, on average, â‰¥3 convulsive 
seizures per month during the past 3 months based on the historic alinformat ion, and the 
patient has â‰¥3 convulsive seizures during a minimum of 4 weeks of seizure data 
collect ion during the prospective Baseline Period
4.Weight of â‰¥10 kg at the Screening visit (Visit 1)
5.Current ly taking 1 to 4 AEDs at a stable dose for 4 weeks prior to the Screening visit
(Visit 1); benzodi azepines used chronically (on daily  frequency) to treat seizures are 
considered AED s
6. If using a vagal  nerve st imulator ( VNS ), must have VNS placed at least 3 months prior to 
the Screening visit with stable settings for >1 month; VNS parameters must remain 
constant throughout the study  (VNS will not be counted as an AED)
7. If on a ketogenic diet, must have started the ketogenic diet at least 3 months prior to the 
Screening vis it (Visit 1), di et shoul d be stable for 4 weeks before the Screening visit 
(Visit 1); and shoul d cont inue through the duration of the study  (ketogeni c diet will not 
be counted as an AED)
8.Failed to become and remain seizure free wit h trials of  at least 2 AE Ds
9.The patient and patientâ€™s legal representative (i .e., parent or legal guardian )are willing to 
keep the AED, VNS, and ketogenic diet regimen(s) stable throughout the study
10.The patient is able to carry  out all appropri ate assessments and take study  drug in the 
opinio n of the Invest igator and parent/caregiver
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 35of 10611.The patient has a documented clinical diagnosis of Dravet syndro me or LGS:
Diagnosis of Dravet syndrome supported by :
ï‚·Onset of seizures around 6 m onths of age
ï‚·Initial seizures
-Fever -induced or fever-triggered seizures
-Hemiclo nic or generalized tonic seizure
-Prolonged seizures (approximately  15 minutes or longer, som e >30 min)
ï‚·Between 1 and 5 y ears, other sei zure t ypes emerge :
-Myoclonic seizures
-Focal  awareness altered
-Absence
-Non-convulsive status (absence or my oclonic)
-Convulsive status epilept icus
ï‚·Development normal within 1styear of life, then intellectual  disabili ty emerges
-May regress wi th recurrent status epilept icus
Diagnosis of Lennox -Gastaut syndrom e supported by:
ï‚·History  of abnorm al EEG consistent wi th LGS 
-EEG wi th slow and/or disorganized background AND one of the following:
oEEG wi th bursts of generalized 2.5 H z (or l ess) spike and wave activit y, -
-OR-
oGeneralized paroxysmal fast activit y (GPFA)
ï‚·Greater than 1 ty pe of  generali zed seizure for at least 6 months
-At least one seizure ty pe wi th drop sei zures
ï‚·Less than 11 y ears of age at the onset of LGS
-Evidence of development delay  or regressi on OR history  of special educat ion 
classed OR measured IQ <70
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 36of 10612. Sexually  active female pat ients of childbearing potent ial (defined as first menarche) must 
agree to use a highly  effect ive method of birth control during the study  and f or 30days
following the last dose of study  drug.
Highly effect ive contraceptive methods are as fo llows:
a.Combined (estrogen and progestogen containing) hormonal contraception 
associ ated wi th inhibit ion of ovulat ion:
ï‚·Oral
ï‚·Intravaginal
ï‚·Transdermal
b.Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation:
ï‚·Oral
ï‚·Injectable
ï‚·Implantable
c.Intrauterine device
d.Intrauterine hormone -releasing system 
e.Bilateral tubal occlusio n
f.Vasectomized partner
g.Sexual abst inence
Sexually  active m ale pat ients (post -pubertal unless permanently sterilized by bilateral 
orchi dectomy) m ust agree to use male contraception (condo m) during the study  and f or a 
minimum o f 90 day sfollowing the l ast dose of study  drug. Male pati ents m ust also not
donate sperm during the Screening and Treatment Periods and for at least 90 days after 
the last dose of study  drug.
6.2. Exclusion Criteria
Patients will be excluded fro m study  enro llment if they meet any o f the following cri teria:
1. T he patient has been admitted to a medical facilit y and intubated for treatment of status 
epilept icus 2 or m ore times in the 3 months immediately prior to the screening visit
2.Non-epilept ic events that cannot be reliably dist inguished from epilept ic seizures
(e.g.,gastroesophageal reflux, muscle cramps, etc.)
3.Patient wit
h history  of confirmed cataract ( untreated with surgery )
4.Unstable, clinically  significant neurol ogic (other than the disease being studied), 
psychiatric, cardiovascular, ophthalmo logic, pulmonary , hepat ic, renal, metabo lic, 
gastrointestinal, urologic, immuno logic, hematopoiet ic, endocrine disease, malignancy 
including progressive tumors, or other abnormalit y, whi ch may  impact the abilit y to 
participate in the study  or that m ay potenti ally confound the study  resul ts. It i s the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 37of 106responsibilit y of the Investigator to assess the clinical significance; however, consult ation 
with the Medical Monitor may  be warranted
5.Any history  of alcoho l, opioid, or other drug use disorder, as per the Diagnostic and 
Statistical Manual o f Mental  Disorders, Fift h Edi tion (DSM -V), within the 2 years 
immediately  prior to the Screening Visit (Visit 1)
6.Suicide attem pt wi thin the last y ear, at si gnificant risk of suicide (either in the opinio n of 
the Invest igator or defined as â€˜yesâ€™ to suicidal ideation quest ion 4 or 5 on the Columbia -
Suicide Severi ty Rating Scale [C -SSRS] at Screening) or appe aring suicidal per 
Invest igator judgment
7.History  of human immunodeficiency  virus (HIV) infect ion (pati ent who has tested 
positive for human immunodeficiency  virus ant ibodies (HIV) -1/2Ab), or history o f active 
hepat itis B, or active hepatit is C infect ion. (Note that patients who have been vaccinated 
against hepatit is B [hepat itis B surface ant ibody  {Ab} -positive] who are negative for 
other m arkers of pri or hepat itis B infect ion [e.g., negative for hepat itis B Core Ab] are 
eligible )
8.Abnorm al and clinically  significant ECG abnormalit y at Screening :
a.QT interval wit h Fridericiaâ€™s correction method (QTcF) >450 ms (males) or >470 ms 
(females), confirmed wit h 1 repeat testing, at the Screening visit
9.Abnorm al clinical laboratory  test resul ts at the Screening visit that suggest a clinically  
significant underlying disease that would compromise the well -being of the patient (if the 
patient has alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]
>2.5 Ã— the upper limit of normal [ULN], the Medical Moni tor shoul d be consul ted)
10.Parti cipated in a clinical study  involving another study  drug in the previous month (or
5half-lives of the study  drug, whi chever i s longer) or currently receiving another study  
drug
11.Received TAK -935 in a previous clinical study  or as a therapeuti c agent
12.Immediate family members, or in a dependent relationship with a study  site em ployee 
who is invo lved in the conduct of this study  (e.
g., child, sibling)
13.Known hypersensit ivity to any  com ponent of the TAK
-935 f ormulation
14.Current ly pregnant or breastfeeding or is planning to become pregnant within 90 days of 
the last dose of study  drug
6.3. Discontinuations
6.3.1. Discontinuation of Patients
The cri teria for enrollment m ust be fo llowed explici tly. If the invest igative site ident ifies a 
patient wh o did not m eet enrollment criteria and who was inadvertently enro lled, the Sponsor 
must be notified immediately. If the Sponsor ident ifies a patient who did not meet enrollment 
criteria and who was inadvertently enrolled, the Investigator site will be noti fied immediately. A 
discussio n must occur between the Sponsor and the Invest igator to determine whether the patient 
may cont inue in the study, with or without study  drug. Inadvertently enrolled pat ients may be 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 38of 106maintained in the study  and on study  drug when the Sponsor agrees with the Invest igator that it
is medically appropriate for that patient. The patient may not con tinue in the study  with or
without study  drug if the Sponsor does not agree wit h the Invest igatorâ€™s determinat ion it is 
medically appropriat e for the patient to continue. The Invest igator must obtain documented 
approval  from the Sponsor to allow the inadvertently  enrolled pat ient to continue in the study  
with or wi thout study  drug.
In addit ion, pati ents will  be discont inued fro m the study  drug (and/or from the study ) in the 
following circumstances:
ï‚·Liver Funct ion Test (LFT) Abnormalit ies
Study  drug shoul d be discontinued immediately with appropriate clinical fo llow up 
(including repeat laboratory tests, until a patientâ€™s laboratory  profile has returned to 
norm al/baseline status, see Section 8.1.11 ), if the following circumstances occur at 
any time during study  drug treatm ent:
-ALT or AST >8 Ã— ULN, or
-ALT or AST >5 Ã— ULN and persists for >2 weeks, or
-ALT or AST >3 Ã— ULN in conjunct ion with elevated total  bilirubin >2 Ã— ULN or 
internat ional norm alized rati o (INR) >1.5, or
-ALT or AST >3 Ã— ULN with appearance of fat igue, nausea, vo miting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
ï‚·QTcF interval >500 ms that is confirmed with a repeat ECG
Study  drug shoul d be discontinued immediately with appropriate clinical follow up
(including repeat ECG)
ï‚·Greater than a 100% increase in 28-dayseizure frequency fro m the 4-week 
prospective Baseline Period (see formula in Section
 8.1.7 ) and considered by the 
Invest igator to be clinically significant worsening of the seizure frequency
ï‚·Not tolerat ing Dose 1 (the lowest dose) for their weight category
ï‚·Enrollment in any other c linical study  involving a study drug or enrollment in any 
other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
ï‚·Depressio n and/or Suicidal Ideat ion
-Study  staff trained in the administrati on of the C -SSRS will assess patient 
suicidali ty using the C -SSRS (see Section 8.1.14 ), elici ting answers f rom the 
patient or the patientâ€™s caregiver. Ultimately, the determinat ionof the presence of  
suicidal ideati on or behavi or depends on the clinical  judgment of  the investigator
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 39of 106ï‚·Invest igator Decisio n (Physician Decisio n)
-The Investigator decides that the patient should be discontinued fro m the study
-If the patient, for any  reason, requi res treatm ent with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
ï‚·Patient Deci sion (Withdrawal by  Patient or Wi thdrawal by Patientâ€™s Legal 
Representative [Parent or Legal Guardian] )
-The pat ient or the patientâ€™s legal representative (i .e., parent or legal guardian)
requests to be withdrawn from the study
ï‚·Sponsor Decisio n
-The Sponsor or its designee discont inues the study or discont inues the patientâ€™s 
participat ion in the study for medical, safet y, regulatory , or other reasons 
consistent with applicable laws, regulat ions, and good clinical pract ice (GCP)
-The Sponsor or its designee stops the clinical study at a partic ular si te
ï‚·Adverse Event
-If the Investigator decides that the patient should be withdrawn because of an 
SAE or a clinically  significant l aboratory  value, the study  drug i s to be 
discontinued and appropriate measures are to be taken. The Sponsor or its 
desig nee is to be alerted immediately (refer to Sectio n 8.3)
Patients who discont inue the study drug and/or study early will have early terminat ion 
proce dures performed as shown in the Schedule of Assessments ( Table 3).
6.3.2. Discontinuation of Study Sites/Site Terminated by Sponsor
Study  site parti cipat ion may be discont inued if the Sponsor or its designee, the Invest igator, or 
the inst itutional review board/independent ethics committee (IRB/IEC) of the study  site judges i t 
necessary  for medical , safet y, regul atory , or other reasons consistent with applicabl
e laws, 
regul ations, and GCP.
6.3.3. Discontinuation of the Study/Study Terminated by Sponsor
The study  will be di scontinued if the Sponsor or its designee judges it necessary  for m edical, 
safet y, regul atory , or other reasons consistent with applicable laws, regu lations, and GCP.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 40of 1067. TREATMENT
7.1. Materials and Supplies
The Sponsor will supply the study sites with TAK-935 100 mg tablets/20 mg mini-tablets and 
matching placebo tablets. TAK-935 tablets/mini-tablets and matching placebo tablets are 
manufactured by SPERA Pharma Inc. (Osaka, Japan) previously named as Takeda 
Pharmaceutical Co. Ltd. Each bottle will contain a label that includes pertinent study information and caution statements.
Clinical study materials will be labeled according to the countryâ€™s regulatory requirements.
If a patient is unable to come for a clinic visit to obtain study drug, the study drug will be 
shipped via a courier service.
7.1.1. Storage
7.2. Treatments Administered
All patients will receive TAK-935 BID orally or vi a gastrostomy tube (G-tube)/percutaneous 
endoscopic gastrostomy (PEG) tube with or wi thout food (patients enrolled in clinical sites in 
China are not to receive study drug via G-tube/PEG tube).
For patients weighing <60 kg at Visit 1, the to tal daily dose of study drug (either placebo or 
TAK-935) is calculated based on body weight at Visit 1 and will be given twice a day (BID). 
The selected doses for the different weight groups are listed in  Table 1.  For patients weighing 
â‰¥60 kg at Visit 1, dosing will be 200 mg/day followed by 400 mg/day, then 600 mg/day ( Table
1). Study drug can be taken with or without food.
Patients weighing <60 kg will be dispensed 20 mg mini-tablets or matching placebo, and patients 
weighing â‰¥60 kg will be dispensed 100 mg tablets or matching placebo. If patients are unable to 
swallow tablets or mini-tablets, formulation can be changed. No change in formulations will be 
made after Visit 4 (Day 36).
Patients will receive the initial dose of study drug, Dose 1, for the first 7 days after
randomization at Visit 2. In the s ubsequent phone call and visit ( phone call 1 [Day 8] and Visit 3 
[Day 15]), the study drug dose will be increased to Dose 2 and Dose 3. The maximum dose for 
any patient will be 600 mg/day. Patients will be contacted by phone within first 2 days following escalation to the maximum dose to assess safety and tolerability of the study drug. Study drug 
dose will be allowed to change in first 6 weeks of the Dose Optimization Period based on the 
judgment of the Investigator and with the approval of the Medical Monitor. The final dose level will be maintained until the end of the Maintenance Period; however, the dose may be decreased 
to the previous lower doses, for safety and tole rability issues. For example, Dose 3 may be CCI
Property of Takeda: For Non-Commercial Use Only aallylyor vor yy
h or wior wh ti
ia Ga G-tub-t
Visit 1, Visit 1
on bodon bo
differeffere n
g will bewill 
 taken wtaken
g <60 kgg <60 
kg will g wil
blets or lets o
er Visitr Vis
ents wilents w
andodomizm
[Day[Dathe Applicable Terms of Useormormatatio
uirremeneme
drug wirug w
y
anyanand Subject to th
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 41of 106reduced to Dose 2 and Dose 2 may be reduced to Dose 1 during Maintenance Period . If Dose 1 is 
not tol erated, the pati ent will be withdrawn fro m the study .
The dose may be increased per Invest igatorâ€™s discretion with approval  of the Sponsorâ€™s Medical 
Moni tor to a maximum of Dose 3 level. All dose changes must be made during the Dose
Optimizat ion Period; dose changes during the Maintenance Period must be discussed and 
approved by  the Sponsor.
Table 1 Dosing Schedule by Weight
Weight (kg) Dose 1 Dose 2 Dose 3
(mg/day)aNo. Tablets/ 
Mini -tablets(mg/day)aNo. Tablets/ 
Mini -tablets(mg/day)aNo. Tablets/ 
Mini -tablets
10-14 80 0/4 160 0/8 220 0/11
15-19 120 0/6 200 0/10 260 0/13
20-24 120 0/6 240 0/12 320 0/16
25-29 120 0/6 240 0/12 360 0/18
30-34 160 0/8 280 0/14 400 0/20
35-39 160 0/8 280 0/14 440 0/22
40-44 160 0/8 320 0/16 480 0/24
45-49 200 0/10 360 0/18 480 0/24
50-54 200 0/10 360 0/18 520 0/26
55-59 200 0/10 360 0/18 560 0/28
â‰¥60 200 2/0 400 4/0 600 6/0
aTotal d oseadministered twice daily .
Two days after each dose titration or taper, patients will be contacted by  phone to m onitor study  
drug compliance, concomitant medicat ion use, and AEs. Any  change in dose will be documented 
in the pat ientâ€™s clinic chart and dosing card. On Days 22, 57, and 113, pati ents will be contacted 
by phone to m onitor com pliance wi th study  drug and seizure diary  and to m onitor AEs.
Tablets/mini -tablets may be crushed and mixed well in applesauce or thick liquid , for taste 
masking, prior to dosing. The amount of applesauce or liquid needed is dependent upon the 
number of tablets /mini -tablets the pati ent is taking. One- half teaspoon or 2.5 mL o f applesauce 
or thi ck liquid is needed for each mini -tablettaken and 2 teaspoons or 10 mL is needed for each 
tablet taken.
For p atients receiving study  drug vi a G-tube/PEG tube, study  drug will be crushed, suspended in 
water, and the suspensio n will be administered via the G -tube/PEG tube using a sy ringe.
Com plete instructi ons will be provided to patients/caregivers in a document p rovided outsi de of 
the protocol. Other medicat ions or enteral feeds should not be given concurrent ly wit h TAK -935. 
Patients enrolled in clinical sites in China are not to receive study  drug vi a G-tube/PEG tube.
If a patient misses a dose, the missed dose s hould be skipped, and the patient should cont inue 
with his/her normal dosing schedule. Skipped doses should be reported as missed doses.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 42of 106Following com pletion of the study , pati ents will have the option to enroll in an OLE study  (under 
a separate protocol; see Secti on5.1) or to enter a double - blind taper period (maximum 14 days). 
During the taper period, the study  drug dose will be de -escalated to a lower dose (taper Dose 3 to 
Dose 2, taper Dose 2 to Dose 1) every  3 days or less frequent ly based on Invest igatorâ€™s discret ion 
until there is no de -escalat ion and study  drug dose is discont inued. After tapering, patients will 
complete a Safet y Follow-up vi sit approximately  15 day s after the l ast dose of study  drug and 
exit the study .
The Investigator or his/her designee is responsible for the fo llowing:
ï‚·Explaining the correct use of the invest igational agent(s) to the patient/site 
personnel/legal representa tive
ï‚·Verifying that instructions are fo llowed properly
ï‚·Maintaining accurate records of study  drug dispensing and accountabilit y
ï‚·Returning or destroying all unused medicat ion to the Sponsor or its designee at the 
end of the study
Patients or the pati entâ€™s legal representative (i .e., parent or l egal guardian) will be instructed to 
contact the Investigator as soon as possible if he or she has a co mplaint or problem wit h the 
study  drug so that the situation can be assessed.
All clinical trial material provided to the Investigator will be stored in a secure and locked place 
and allocated and dispensed by the interact ive web -response system ( IWRS ). The allocat ion and 
dispensing of the study  drugs will be fully  documented. Detailed records of the amounts of the 
study drug received, dispensed, and remaining at the end of the study will be maintained.
TAK -935 or pl acebo tabl ets/mini -tablets shoul d be administered at approximately  the same t imes 
on each day . The actual  time of all dose administrations prior to PK samp le collection will be 
recorded in the patientâ€™s source documents and transcribed into electronic case report form 
(eCRFs).
7.3. Method of Assignment to Treatment
Patients who m eet all cri teria for enrollment will be randomized to double -blind treatment at 
Visit2. Assignment to treatment groups will be determined by a co mputer -generated random 
sequence using an IWRS. The IWRS will be used to assign tablets/mini -tablets containing 
doubl e-blind study  drug to each patient.
To achieve between -group com parabilit y, randomization will be stratified.
At Visit 2, all eligible pat ients will be stratified by 2 categories: patients with Dravet syndrome 
with convulsive seizures, and LGS patients with drop seizures to ensure balance of treatments 
within each stratum .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 43of 106Note that patients with the minimum number of convulsive or drop seizures will be assigned to a 
stratum following these stratification rules:
Patients with Dravet syndrome:
!46 eligible patients diagnosed with Dravet syndrome with â‰¥3 convulsive seizures per
28 days during the prospective Baseline Period will be randomized into the Dravet 
syndrome stratum
Patients with LGS (Lennox Gastaut Syndrome):
!80 eligible patients diagnosed with LGS with â‰¥4 drop seizures per 28 days during the 
prospective Baseline period will be randomized into the LGS stratum
If a patient does not meet any of these, the patient will be considered a screen failure.
7.4. Continued Access to Study drug
7.5. Blinding
This is a double-blind study.
Emergency unblinding for AEs may be performed t hrough an IWRS. This option may be used 
ONLY if the patientâ€™s well-being requires know ledge of the patientâ€™s treatment assignment.
All calls resulting in an unblinding event are recorded and reported by the IWRS.
If an Investigator, site personnel performing assessments, or patient is unblinded, the patient 
must be discontinued from the study. In cases where there are ethical reasons to have the patient remain in the study, the Investigator must obtain specific approval from the Sponsor Medical 
Monitor for the patient to continue in the study.
Unblinding should only be considered for the safety of the patient. If unblinding is deemed 
necessary by the Investigator, the Investigator can unblind the patientâ€™s treatment allocation 
using IWRS. The Investigator must note the date, time, and reason for unblinding.
The Investigator should inform the Sponsor that the patient was unblinded, however they are not 
required to reveal to the Sponsor the patientâ€™s treatment allocation.
When an AE is an unexpected related SAE, the blind will be broken by the Sponsor only for that 
specific patient. The blind will be maintained for persons responsible for the ongoing conduct of the study (such as the monitors, Investigators , etc.) and those responsible for data analysis and 
interpretation of results at the conclusion of the study, such as biometric s personnel. Unblinded 
information will only be accessible to those who need to be involved in the safety reporting to Health Authorities, Ethics Committees, and/or IRBs.
Investigators will receive only blinded information unless unblinded information is judged 
necessary for safety reasons.CCI
Property of Takeda: For Non-Commercial Use Only and Subjeed throud thr
owledgewledg
are recore rec
orming ormin
dyy. In ca. In c
gator muator m
ntinue itinue 
be cons con
stsigatorigat
Investnvest igi
or shour sho
reveal tevea
n AE in AE
ific patific pa i
e studystu
intinte Applicable Terms of Use during during
failure.ailure.
erpre
infinbject to the A
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 44of 1067.6. Concomitant Medications and Non-Pharmacologic Therapies and
Procedures
Adjunctive antiepileptic drug (AED) treatment, (medical) marijuana, cannabidiol products, VNS 
settings, and ketogenic diet should not be altered during the study. Concurrent treatment regimen 
data will be collected throughout the study.
All medication including vitamin supplements, ove r-the-counter medications, and herbal 
preparations including (medical) marijuana and cannabidiol products will be collected 
throughout the study.
Use of perampanel from screening through follow-up is prohibited.
Use of traditional Chinese medicines should be approved by the Medical Monitor at screening.
7.7. Treatment Compliance
Patient compliance with study medication will be assessed at each visit. On in-clinic dosing days, 
after administration of study drug, appropriate mouth and/or hand checks will be performed to ensure that the dose is swallowed and noted in the source document. If a site visit is not possible 
during the morning hours, the patient should take their morning dose prior to attending the visit 
during the afternoon hours. The date and time of dose given in the clinic will be recorded in the source documents and on the eCRFs.
Patients and/or patientsâ€™ caregivers will be required to bring study drug/unused study drug and 
the daily recording in the dosing card to each dispensing site visit. All patients and/or patientsâ€™ caregivers should be re-instructed about the dosing requirements during study contacts. The 
authorized study personnel conducting the re-education must document the process in the patient 
source records.
Patients who are significantly noncompliant will be discontinued from the study. A patient will 
be considered significantly noncompliant if he  or she intentionally misses more than 20% of 
study medication during the study. Similarly, a patient will be considered significantly noncompliant if he or she is judged by the Investigator to have intentionally or repeatedly taken 
more than the prescribed amount of medication.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to thee MedicMed
esssed atsed 
uth and/h and
the sourthe sou
take thtake th
time of ime o
s will will beb
g card tocard 
ucted abcted a
el condul cond
gnificangnifica
ignificanignific
tiooTerms of Use
n dun d
iant if hant if 
han the pan thehe Applicable T
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 45of 1068. STUDY ASSESSMENTS
The fo llowing sect ions describe the study  procedures to be performed and data to be collected. 
For each procedure, patients are to be assessed by the same Invest igator or site personnel 
whenever possible. Study  procedures and their timing (including tolerance limits for timing) are 
summarized in the Schedule of Assessments ( Appendix 1,Table 3).
Appendix 2lists the laboratory tests that will be performed for this study .
Appendix 3provi des a summary  of the m aximum  number and vol ume of invasive samples, for 
all sampling, during the study .
8.1. Study Procedures
8.1.1. Informed Consent Procedure
The requi rements of the informed consent are described in Section
 11.1.
8.1.1.1. Study Informed Consent Procedure
Inform ed consent m ust be obtained before the patient enters into the study , and before any  
protocol -directed procedures are performed .
The informed consent f orm must be signed by the patientâ€™s legally  authori zed representative. A 
verbal or written patient assent should be obtained fro m the pati ent, if applicable, in the event the 
patient is not capable of providing an informed consent. If the patient is not ca pable of providing 
an assent, the reason should be documented by the Invest igator.
A unique patient ident ificat ion (ID) number (patient number) will be assigned to each patient and 
will be used throughout the study .
8.1.2. Demographics, Medical History, and Medic ation History Procedure
Dem ographic informat ion to be obtained will include year of birth (asallowed per local 
regul ations), gender, ethnicit y, and race as described by  the pat ient/caregiver. Height and weight 
will be co llected at Screening (Visit 1).
Medical history  to be obtained will include determining whether the patient has any significant 
condi tions or di seases rel evant to the di sease under study  that resolved at or before signing of 
inform ed consent. Ongoing condit ions are considered concurrent medical condit ions.
Medicat ion history  informat ion to be obtained includes any medicat ion relevant to eligibilit y 
criteria and the efficacy or safet y evaluat ions stopped at or within 28 days before signing of 
inform ed consent. AED history  will be collected as part of the medicat ion history  informat ion.
8.1.3. Physical Examination Procedure
The physical examinat ion will  consist of the following body  systems: (1) head, eyes, ears, nose, 
and throat; (2) cardiovascular system; (3) respiratory  system; (4) gastrointest inal system; 
(5)dermatologic system; (6) extremit ies; (7) musculoskeletal system; (8) lymph nodes; 
(9)psychiatric status; and (10) other. All examinatio ns are to be performed by the Invest igator or 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 46of 106a qualified site staff member. The physical examination must be captured in the source document 
and eCRF.
8.1.4. Neurological Examination Procedure
A separate neurological examination will be performed and collected in the eCRF. This will 
include testing mental status, gait, cerebellar function, cranial nerves, motor function, and 
sensation.
8.1.5. Weight and Height
Weight and height are to be measured while the patient is wearing indoor clothing and with 
shoes off. If unable to obtain height or wei ght, data may be collected  from other sources
(e.g., medical records or the patientâ€™s caretaker). The Investigator must document in the source 
document the reason for not obtaining height or w eight (e.g., the patient is in a wheelchair).
8.1.6. Vital Signs Procedure
Vital signs to be measured are temperature, blood pressure, heart rate (beats per minute), and 
respiratory rate. 
Vital signs should be measured at the same time of  day across visits, if possible. When vital 
signs are scheduled at the same time as blood draws, the blood draw will take priority and vital 
signs will be obtained within 15 minutes before or after the scheduled blood draw, if possible.
All vital signs data collected at study visits will be recorded on the source documents and in the 
eCRF.
8.1.7. Seizure Diary Procedure
The seizure diary is an observer-reported clinical outcome assessment measure that captures the 
total number of motor seizures (i.e., drop seizures,  tonic-clonic, tonic, bilateral clonic, atonic, 
myoclonic-atonic, myoclonic-tonic-clonic, focal seizures with bilateral hyperkinetic motor features) by type, in accordance with the new seizure classification system .
7Patients and/or 
patientsâ€™ caregivers will be the observers and reporters in the current study. Patients and/or 
patientsâ€™ caregivers may record seizures throughout the day and must ensure that the daily diary 
assessment is completed each evening, even if no seizures occurred.
Drop seizures are defined as a seizure involvi ng the entire body, trunk, or head that leads to a 
fall, injury, slumping in a chair, or head hitting the surface, or could have led to a fall or injury, depending on the position of the patient at the time of the attack or spell. Drop seizures will be 
counted separately for patients enrolled in LGS stratum (e.g., tonic seizures or generalized tonic 
clonic seizures leading to a drop will be captured as a drop). Convulsive seizures include CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useng indoog indo
llected lected
tigator igator
(ee.g.g., th, th
ood presod pre
amame time tim
as blooas blo
minutes inute
at studyt stud
iaiary Prry P
y is an oy is an 
of motorf moto
atoniatoni c,c
) by by tytyyypyy
ntsâ€™ntsâ€™careca
atientsâ€™ centsâ€™
assessmassess
DrDe Applicable Term
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 47of 106generalized tonic -clonic, fo cal to bilateral  tonic -cloni c with impai red awareness, hemi -clonic and 
simultaneous bilateral clo nic (generalized clo nic) seizures.
At the Screening visit (Visit 1) and at every  clinic visit, the patient and/or patientâ€™s caregiver will 
be given a seizure d iary and specific instructions to ensure compliance with the seizure 
recording. The seizure events will be recorded starting at the Screening/Baseline Period up until 
the Follow -up Visi t. At each clinic visit, the diary will be collected and reviewed by th e 
Invest igator with the patient and/or patientâ€™s caregiver for proper recording.
For the prospective Baseline Period, the seizure frequency will be calculated as
(# of seizures) / (# of days seizures were assessed) ï‚´28
Seizure fre quency calculated through this method will be used to confirm the eligibilit y. 
8.1.8.
Documentation of Study Drug
A dosing card will be provided to the patient and/or caregiver at each clinic visit to record actual 
time of the last 2 dose administrations prior to PK sample collect ion, to record exact time of the 
last m eal rel ative to dosing prior to PK or PD sample co llection,and to record any  changes in 
dosing regimen that may  occur between visits and during the de -escalation period of the study; 
these will be recorded in the patientâ€™s source documents and transcribed into electronic case 
report form s(eCRFs).
8.1.9. Documentation of Concomitant Medications
Concomitant medicat ion is any drug given in addit ion to the study  drug. These may  be
prescribed by  a physician or obtained by  the pat ient over the counter. Concomitant medicat ion is 
not provi ded by  the Sponsor. At each study  visit, pati ents and/or caregivers will be asked
whether patients have taken any medicat ion other than the study  drug (used from signing of
inform ed consent through the e nd of the study ), and all  medicat ion including vitamin 
supplements, over -the-counter m edicat ions, and herbal preparat ions, m ust be recorded in the 
source document and eCRF. Documentation will include generic medication name, dose, unit, 
frequency , route of administration, start and end dates, and reason for use.
AED treatment, VNS settings, and ketogenic diet should not be altered during the study .
8.1.10. Documentation of Concurrent Medical Conditions
Concurrent medical condit ions are those significant ongoing condi tions or di seases that are 
present at signing of informed consent. These include clinically  significant l aboratory , ECG, or 
physical examinat ion abnormalit ies noted at Screening (Visit 1), according the judgment of the 
Invest igator. The condit ion (i.e., diagnosis) should be described and recorded on the Medical 
History  form.
8.1.11. Procedures for Clinical Laboratory Samples
Blood and urine samples are to be collected at the time points stipulated in the Schedule of 
Assessments ( Table 3). Sam ples will be collected in accordance wit h acceptable laboratory  
procedures. Details of these procedures and required safet y monitoring will be given in the 
laboratory  manual.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 48of 106The clinical laboratory  tests to be performed are listed in Appendix 2.
For an individual pat ient, the maximum vo lume of blood collected over the c ourse of the study  
will be 73.2 mL (Appendix 3). As this is a pediatric study , blood vol ume limitat ions will 
sometimes preclude the co llection of all samples in a particular study  visit.
 Appendix 3
enumerates the priorit ies for blood collect ion. 
In general, exist ing guidelines for blood sample volume limits (ranging fro m 1% to 5% of total 
blood volume wit hin 24 hours and up to 10% of total bl ood vol ume over 8 weeks) are consistent 
with the limi ted evidence available on â€œminimal riskâ€ to children. Examples of guidelines for 
blood draw limit s in pediatrics can be found at: h ttp://www.who.int/bullet in/volumes/89/1/BLT -
10-080010- table - T2.ht ml.
Thecentral  laboratory  will perform  laboratory  tests for hem atology, serum  chemistry , and 
urinalysis. The results of clinical laboratory  tests will  be returned to the Invest igator, who is 
responsible for reviewing and filing these results. The Investigator wi ll maintain a copy  of the 
laboratory  accredi tation and the reference ranges for the laboratory  used.
If pat ients experience ALT or AST >3 Ã— ULN, follow- up laboratory tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be performed preferably 
within 48 to 72 hours and no later than 5 day s after the abnormalit y was noted. Pl ease refer to 
Secti on6.3.1 for discontinuat ion criteria and Section 8.3.3.1 for reporting requirements related to 
ALT or AST >3Ã—ULN in conjunct ion with total  bilirubin >2Ã—ULN.
If the ALT or AST remains elevated >3 Ã— ULN on these 2 consecut ive occasio ns, the 
Invest igator must contact the Medical Monitor for consideration of addit ional testing, close 
monitoring, possible discont inuat ion of study  drug, and discussion o f the relevant patie ntdetails 
and possible alternat ive etio logies. The abnorm ality should be recorded as an AE (please refer to 
Secti on 8.3.3.1 for reporti ng requirements).
If urine cannot be collected due to the patientâ€™s cooperation or because the patient is wearing a 
diaper, the reason should be documented in the source document a nd, for sexually active female 
patients, the results of the serum pregnancy  test obtained at Visit 1 must be confirmed to be 
negat ive by the Invest igator prior to randomizat ion.
8.1.12. Contraception and Pregnancy Avoidance Procedure
Please refer to Section 6.1for detailed contraception requirements.
Patients will  be provi ded wi th information on acceptable methods of contraception as part of the 
patient inf ormed consent process and will be asked to sign a consent form stating that they  
understand the requirements for avoidance of pregnancy, donation of ova, and sperm donation 
during the course of the study  and for 90 days after the l ast dose of study  drug. T his may be 
signed by the l egally authori zed representative of the pat ient.
All sexually  active female pat ients of childbearing potential must have a negat ive serum/urine 
hCG pregnancy test at Screening (Visit 1) and a negative urine hCG pregnancy test on D ay 1 
(Visit 2), before receiving any  dose of study  drug. If urine cannot be collected at Visit 2, the 
reason should be documented in the source document, the results of the serum pregnancy test 
obtained at Visit 1 must be confirmed to be negat ive by the In vestigator prior to randomizat ion, 
and results of a serum pregnancy test at Visit 2 must be confirmed to be negat ive before the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 49of 106patient can receive the first dose of study  drug. During the course of the study , pati ents will 
receive cont inued guidance with respect to the avoidance o f pregnancy and ova or sperm 
donati on as part of the study  procedures. An addit ional serum/urine hCG pregnancy test will be 
perform ed at the Final Visit .
Sexually  active m ale pat ients (post -pubertal unless permanently sterilized by bilateral 
orchi dectomy) m ust agree to use male contraception (condom) during the study  and f or a 
minimum o f 90 days following the l ast dose of study  drug. Male pati ents must al so not donate 
sperm  during the Screening and Treatment Periods and for at least 90 days after the last dose of 
study  drug.
8.1.13. ECG Procedure
A 12 -lead ECG will be recorded at Screening (Visit 1) and at 30 min (Â±10 min) after the morning 
dose at other visit s. If the pati ent cannot tol erate being supine, a sitting ECG may  be obtained. 
The Investigator (or a qualified observer at the study  site) will  interpret the ECG using 1 of the 
following categori es: wi thin norm al limits, abnormal  but not clinically significan t, or abnorm al 
and clinically  significant. The interpretation of the ECG will be recorded in the source 
docum ents and in the eCRF. The time that the ECG was performed will be recorded. The
following parameters will be recorded on the eCRF from the pat ientâ€™s ECG trace: heart rate, RR 
interval , PR interval, QT interval, QRS interval with QTcF, and corrected QT interval. ECG 
traces recorded on thermal paper will be photocopied to avoid degradat ion of trace over time.
8.1.14. Clinical Assessment of Suicidal Ideation an d Behavior
Suicidal  ideati on and behavi or will  be assessed in children aged â‰¥6 years by the use of the 
C-SSRS. The C- SSRS is a 3- part scale that measures suicidal ideat ion (e.g., pati ent endorses 
thoughts about a wish to be dead or has other thoughts of su icide), intensit y of ideation 
(frequency), and suicidal behavior (actually, interrupted, and aborted attempts at suicide)
.8
Two versions of the C-S SRS will be used in this study , the Screening/Baseline C- SSRS Lifet ime 
and the Since -Last-Visit C-SSRS.
Study  staff trained in the administration of the C -SSRS will assess patient suicidalit y using the 
C-SSRS, elicit ing answers fro m the pati ent or the pati entâ€™s caregiver . Ultimately, the 
determinat ion of the presence of suicidal ideation or behavior depends on the clinical judgment 
of the invest igator .
If a patient exhibits signs of suicidal ideation, the patient may  be discont inued as described in 
Secti on 6.3.1 .
8.1.15. Aberrant Behavior Checklist
Behavior will be assessed by  the use of the ABC -C questi onnaire, which is a rating scale that 
measures the severit y of a range o f probl em behaviors comm only observed in individuals wit h 
intellectual  and devel opmental  disabili ties.9It is completed by  the caregiver. It i s an empirically  
developed scale designed to measure psychiatric symptoms and behavioral disturbance exhibited 
by individuals across 5 domains wit h 58 i tems: irritabili ty, agitation, and crying (15 items); 
lethargy , social  withdrawal  (16 i tems); stereoty py (7 items); hyperact ivity/nonco mpliance 
(16items); and inappropriate speech (4 items).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 50of 106If the patient is unable to comply wit h the ABC -C,for example due to the l anguage barri er 
(e.g.,unavailabilit y of validated test in patientâ€™s language) ,the Invest igator may also use clinical 
judgment to assess for behavior.
8.1.16. Vineland Adaptive Behavior Scale
The Vineland Adapt ive Behavior Scales, 3rd Edit
ion, Parent Caregiver Form (VABS -3 Parent 
Caregiver Form), is a parent -report questionnaire of adaptive funct ioning or how an individual 
behaves in their day -to-day life at ho me and in the communit y.10It assesses adaptive funct ioning 
across 4 domains : probl em behavi or, communicat ion, daily living, and socialization. The 
questionnaire takes about 20 minutes to complete.
If the patient is unable to comply wit h the VABS , for example due to the language barrier 
(e.g.,unavailabilit y of validated test in patientâ€™s l anguage), the Invest igator may also use clinical 
judgment to assess for adaptive funct ion and behavior.
8.1.17. Quality of Life in Childhood Epilepsy
The Qualit y of Life in Childhood Epilepsy  is a parent -reported questionnaire that evaluates 
healt h rela ted qualit y of life in children ages 4 to 18 years old. It con tains 76 i tems with 
16subscales covering 7 domains of life function: physical act ivities, social act ivities, cognit ion, 
emotional wellbeing, behavi or, general  health, and general qualit y of life.
8.1.18. Sleep Disruption Numerical Rating Scale
The patientâ€™s caregiver will be asked:
â€œOn a scale o f â€˜0 to 10â€™, please circle the number that best describes y our childâ€™s sleep 
disrupt ion in the last week.â€
The m arkers range from 0 (slept extremely  well) to 10 (unable to sleep at all). If the main 
caregiver is not available at the appropriate visit then this information can be captured over the 
telephone, i deally on the day  of the visi t or otherwise wi thin 3 days.
8.1.19.
Caregiver Global Impression of Change (Care GI- C)
At Visit 2 (prior to administration of the first dose of study  drug), the caregiver will be asked to 
write a brief descript ion of the patientâ€™s overall condit ion as a memory aid for the Care GI -C at 
subsequent visits.
The Care GI -C com prises the foll owing question to be rated on a 7 -point scale:
Since y our child started treatm ent, pl ease assess the status of y our childâ€™s overall condit ion
(com paring their condit ion now to their condit ion before treatment) using the scale below.
ï‚·Very  Much Im proved
ï‚·Much Improved
ï‚·Slightly Improved
ï‚·No Change
ï‚·Slightly Worse
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 51of 106!Much Worse
!Very Much Worse
If the main caregiver is not available at the appropriate visit then this information can be 
captured over the telephone, ideally on the day of the visit or otherwise within 3 days.
8.1.20. Clinicianâ€™s Clinical Global Impression of Severity and Change (CGI-S/C)
CGI-Severity (CGI-S) is used to obtain an asse ssment of symptoms severity. The CGI-S focuses 
on cliniciansâ€™ observations of the patientâ€™s cognitive, functional, and behavioral performance 
since the beginning of the study . The CGI-S/C measure s improvement from the first assessment.
The CGI-S is rated on a 7-point scale, with the severity of illness scale using a range of 
responses from 1 (normal) through to 7 (amongst the most severely ill patients).
For the CGI-Change (CGI-C) treatment response ratings should take account of both therapeutic 
efficacy and treatment-related AEs and range fro m 0 (marked improvement and no side-effects) 
and 4 (unchanged or worse and side-effects outweigh the therapeutic effects). Each component 
of the CGI is rated separately; the instrument does not yield a global score.
The PI or designee will complete the CGI-S/C at the timepoints specified in  Table 3.
8.1.21. Early Termination
Early Termination/Exit survey will be conducted at Visit 6 and takes approximately 2 minutes. 
The survey captures the parentâ€™s (and caregiv erâ€™s) experiences with TAK-935 including impact 
of treatment with TAK-935 on daily life/functioning and on most important bothersome 
symptoms.
8.1.22. Pharmacokinetic Sample Collection and Analysis8.1.22.1. Collection of Plasma Samples for TAK-935 and M-I PK Evaluation
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useocuses cuses 
mmance ance
assessmassess
ange oange o f
ts).).
ount of bnt of
ement anment 
ic effectc effec
obal scobal sc
ints spents sp
t Visit Visit 6
s) expes) exp
ctiooningnin
le Collee Col
ma Sama Sam
mm
perty of Takeda: For Non-Comm
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 52of 1068.1.22.2. Bioanalytical Methods for TAK-935 and M-I
Plasma concentrations of TAK-935 and M-I will be measured by high-performance liquid 
chromatography with tandem mass spectrometry.
8.1.22.3. Pharmacokinetic Parameters
8.1.23. Pharmacodynamic Sample Collection and Analysis
8.1.23.1. Collection of Plasma Samples for Pharmacodynamic EvaluationCCI
CCI
CCI
Property of Takeda: For Nrmacodrmaco
CollecColleand Subject to the Applicable Terms of Used byd by highiyythe Applicable Terms of Use
Non-Commercial Use Only an
perty of Takeda
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 53of 1068.1.23.2. Bioanalytical Methods for 24HC
8.1.23.3. Pharmacodynamic Parameters
The PD parameter of change from Baseline in plasma 24HC levels will be summarized. 
Additional PD parameters may be calculated, as appropriate.
8.1.23.4. Documentation of Screen Failure
Investigators must account for all patients with a signed informed consent. If the patient is f ound 
to be ineligible for the study at this visit, the Investigator will enter the reason in the IWRS. The IWRS should be contacted as a notification of screen failure.
The primary reason for screen failure is to be recorded in the IWRS. Patients may be re-screened 
after consultation with the Med ical Monitor.
Patient ID numbers assigned to patients who fail screening should not be reused. If a patient fails 
screening, but is later successfully rescreened, the data for the patient will be entered as if these 
were 2 separate patients. Therefore, the data should be entered as follows:
1. The screen failure data should be entered as a screen failure patient.
2. Rescreened patients should be assigned a new patient ID number and treated as a 
stand-alone patient.
8.1.23.5. Documentation of Study Entrance
Only patients who meet all of the inclusion crit eria and none of the exclusion criteria are eligible 
for randomization into the study.
If the patient is found to be not eligible, the Investigator should record the primary reason for 
failure on the applicable IWRS.CCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to thevels willels w
gned inned i
estigatostiga
f screenscree
o be reco be re
onitor.nitor.
atients wients 
ully rescly res
erefore,refore
re data se data
patpatieientn
ne patne patplicable
iei
DocumDocu
atients wtients
andomindom
If the pathe p
failurfailuhe ApplifU s e
ble Terms of U
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 54of 1068.2. Sample Collection and Testing
Appendix 1 lists the schedule for sample collections in this study. 
Appendix 2 lists the laboratory tests that will be performed for this study.
Appendix 3 provides a summary of the maximum number  and volume of invasive samples, for 
all sampli ng, during the study.
8.2.1. Optional Blood Samples for Storage: 
Samples for research purposes are optional and will be collected as specified in the Schedule of 
Assessments (Table 3) . 
The optional blood samples w ill be coded with the patient number and stored for up to a 
maximum 15 years after the last patient visit for the study at a facility selected by the s ponsor. 
The samples and any data generated from them can only be linked back to the patient by the Investigator or site personnel. The duration allows the sponsor to respond to regulatory requests 
related to the study drug.
Samples will be destroyed according to a process consistent with local regulation. Patients may 
request to have their samples destroyed at any time.
8.3. Safety Evaluations
Investigators are responsible for monitoring the saf ety of patients who have entered this study 
and for alerting the Sponsor or designee to any even t that seems unusual, even if this event may 
be considered an unanticipated benefit to the patient.
The Investigator is responsible for the appropriate medical care of patients during the study. The 
Investigator remains responsible for following, through an appropriate health care option, AEs that are serious, considered related to the study  treatment or the study, or that caused the patient 
to discontinue before completing the study. The patient should be followed until the event is 
resolved or explained. Frequency of follow-up evaluation is left to the discretion of the Investigator.
8.3.1. Adverse Events
An AE is any untoward medical occurrence in a patient or clinical study patient administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable or unintended sign (for example, an abnormal CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subjectected as ted a
atient nutient n
he studyhe stud
 can oncan on
allows tllows
to a proto a p
royoyed ated 
ationsions
sible forible f
ponsor ponso
unanticipnantic
tor is resr is re
r remainrema
serious,serious
contcontinuin
solved oolved
Investnvest igrms of Use
8.8ct to the Applicable Term
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 55of 106laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a m edicinal 
product, whether considered related to this medicinal product.
The definit ion of an AE also covers medicat ion errors and uses outside what is foreseen in the 
protocol  only  if an AE resul ts from the error, including in tentional misuse, abuse, and overdose 
of the product. Adverse events (including S AEs)associ ated wi th overdose should be reported 
according to the procedure outlined in Section 8.3.1.5 . In the event of drug overdose, the patient 
shoul d be treated symptomat ically .
Situations where an untoward medical occurrence did not occur (social and/or convenience 
admissio n to a hospital) and anticipated day -to-day fluctuations of pre-exist ing disease(s) or 
condi tion(s) present or detected at the start of the study  that do not worsen are not AEs.
Ovid has standards for reporting AEs that are to be fo llowed regardl ess of applicable regulatory  
requi rements that m ay be less stringent.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish drug effect.
Cases of pregnancy that occur during maternal or paternal exposures to study  drug are to be 
reported. Data on fetal outcome and breast -feeding are collected for regulatory  reporting and 
drug safet y evaluat ion.
Study  site personnel  will record the occurrence and nature of each patientâ€™s pre -exist ing 
condi tions, including clinically  significant si gns and symptom s of the disease under treatm ent in 
the study .
Seizures in this pat ient population will be measured using the seizure diary and seizure frequency 
as a primary study  endpoint (see Secti on8.1.7 ). For the purpose of this study , reporting of 
seizures should meet the AE/SAE reporting requirements. As seizures are considered a baseline 
condi tion, seizures shoul d be reported as an AE/SAE if: 1) there is a clear increase in the 
frequency  of seizures co mpared to the pati entâ€™s baseline, 2) there is an emergence of a new 
seizure ty pe, or 3) the patient experiences status epilept icus, and 4)any other time the 
Invest igator feels the seizure should be captured as an AE/SAE, in which case the Investigator 
shoul d docum ent his/her reasoning. All seizures will be captured in the seizure diary  collected at 
the site during the study  and will be analyzed by  the Sponsor along wit h the reportable SAEs in 
evaluat ing risk:benefit. The Sponsor will report the SAE events of seizure that meet these criteria 
in an aggregated unblinded report at the conclusio n of the stud y.
After the informed consent form (ICF) is signed, site personnel will record any change in the 
condi tion(s) and the occurrence and nature of any AEs. If a pa tient experi ences an AE after 
signing informed consent, but prior to receiving study  drug, the event will be reported, but will 
be included in the patientâ€™s medical history  unless the event is serious, or the Invest igator feels 
the event may have been caus ed by a protocol procedure.
In addit ion, all AEs occurring after the patient receives the first dose of study drug must be 
reported to Ovid or its designee via the eCRF.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 56of 1068.3.1.1. Severity Assessment
Invest igators will be instructed to rate the severit y of AEs using the following cri teria:
Mild Events require minimal or no treatment and do not interfere with the patientâ€™s daily 
activities.
Moderat e Events result in a low level of inconvenience or concerns with the therapeutic measures. 
Moderate events may cause som e interference with functioning.
Severe Events interrupt a patientâ€™s usual daily activity and may require systemic drug therapy or 
other treatment. Severe events are usually incapacitating.
Change in severit y of an AE shoul d be docum ented based on specifi c gui delines in the eCRF 
Com pletion Guidelines.
Severit y and seri ousness m ust be differentiated: severit y describes the intensit y of an AE, while 
the term  seriousness refers to an AE that has met the criteria for an SAE.
8.3.1.2. Causality Assessment
Invest igators will be instructed to report to Ovid or its designee their assessment of the potential 
relatedness of each AE to protocol procedure and/or study  drug via the CRF.
An Invest igator causalit y assessment (unrel ated or rel ated) m ust be provi ded for all  AEs (bot h 
serious and non -serious). This assessment m ust be recorded in the CRF and any addit ional forms 
as appropri ate.
Relationship of AEs to the defined study  treatm ent (TAK -935 [after the start of TAK -935 on 
Day 1]), will  be determined by the Invest igator acco rding to the fo llowing criteria. Please note 
that not all criteria must be present to be indicat ive of a particular relat ionship.
Not Related Exposure to the defined study treatment did not occur, or the occurrence of the AE is 
not reasonably related in t ime
Unlikely Related The AE occurred in a reasonable time after the defined study treatment and is 
doubtfully related to the investigational agent/procedure
Possibly Related The defined study treatment and the AE were reasonably related in time, and the AE 
could be explained equally well by causes other than exposure to the defined study 
treatment
Related The defined study treatment and the AE were reasonably related in time, and the AE 
was more likely explained by exposure to the defined study treatment than by other 
causes, or the defined study treatment was the most likely cause of the AE
If a patientâ€™s dosage is reduced or treatment is discontinued as a result of an AE, study  site 
personnel must clearly  report to Ovi d or i ts desi gnee via CRF the circumstances and data leading 
to any  such dosage reduction or discont inuat ion of treatm ent.
8.3.1.3. Serious Adverse Events
Serious adverse event collect ion begins after the patient has signed informed consent. If a patient 
experiences an SAE after signing informe d consent, but prior to receiving study  drug, the event 
will be reported, but will be classified as a pre -treatm ent SAE unl ess the Investi gator f eels the 
event m ay have been caused by  a protocol  procedure.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 57of 106Planned surgeries and/or hospitalizat ions should not be reported as SAEs unless the underlying 
medical condit ion has worsened during the course of the study .
Study  site personnel  must al ert Ovi d or i ts desi gnee of  any SAE within 24 hours of Invest igator 
awareness o f the event via a sponsor -approved method. If  alerts are i ssued via tel ephone, they  
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms. This
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE
inform ation.
An SAE is any  AE from this study  that resul ts in 1 or m ore of the fo llowing outcom es:
ï‚·Results in death
ï‚·Requi res or prol ongs hospi talizat ion
ï‚·Is life threatening (that is, immediate risk of dying)
ï‚·Persi stent or si gnificant disabilit y/incapacit y
ï‚·Congenital ano maly or bi rth defect
ï‚·Other medically important serious event
Important m edical events that may not result in death, be life -threatening, or require 
hospi talizati on may  be considered seri ous adverse drug events when, based upon appropriate 
medical judgment, they  may jeop ardize the patient and may require medical or surgical 
intervent ion to prevent one of the outcomes listed in this definit ion.
Serious adverse events occurring up to and including the patientâ€™s last study  visit will  be 
collected, regardless of the Investiga torâ€™s opinion of causat ion.
If an Invest igator becomes aware of SAEs occurring to a patient after the patientâ€™s participat ion 
in the study  has ended (including any  protocol -requi red post -treatm ent follow-up), the 
Invest igator should report the SAEs to the sponsor, regardless of the Investigatorâ€™s opinio n of 
causat ion.
8.3.1.4. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the Invest igator identifies as related to study  drug or procedure. United States
21 CFR 312.32 and European Unio n Clinical Trial Directive 2001/20/EC and the associated 
detailed guidance or national regulatory  requi rements in parti cipat ing countries require the 
reporting of SUSARs. Ovid has procedures that will be fo llowed f or the recording and expedited 
reporting of SUSARs that are consistent with glo bal regul ations and the associated detailed 
guidance.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 58of 1068.3.1.5. Reporting Adverse Events
All non-serious AEs must be recorded in the eCRF upon awareness.
Any AE that meets SAE criteria ( Section 8.3.1.3)  must immediately (i.e., within 1 business day) 
be sent to the Sponsor upon learning of any SAE that occurs (whether or not attributable to the study drug). It is the I nvestigatorâ€™s responsib ility to ensure that SAE re porting procedures are 
followed appropriately. All SAE reports and any revisions to an SAE report must be sent to the 
following fax number or email. All supporting source information concerning the SAE (e.g., hospital records) should als o be provided by fax or email.
Country-specific fax numbers will be provided in a separate document.
Email : 
If there is a question concerning an SAE, the site needs guidance regarding reporting of an SAE, 
the site is returning a call from the Sponsorâ€™s safety specialist, or the site urgently needs to report 
an SAE or make the Sponsor aware of an SAE, the safety hotline should be used(country-specific hotline numbers provided in a separate document).
If an SAE is reported via the hotline, the site should first submit the SAE paper form and then 
enter the SAE in the eCRF. Any AE that meets SAE criteria must be entered into the EDC 
system immediately (i.e., within 1 business day)  after site personnel first learns about the event 
in addition to faxing/emailing the SAE Report form. Once the qualifying SAE data are entered 
into EDC, the Sponsor will be notified by an email alert, which will contain high-level safety information.
All SAEs must be reported starting from the time that informed consent for study participation is 
provided. If the Investigator becomes aware of an SAE within 30 days after the patientâ€™s last 
dose of study drug or within 30 days after the last st udy visit, the SAE must be reported. Serious 
AEs must be followed until the event resolves, the event or sequelae stabilize, or it is unlikely 
that additional information can be obtained after demonstration of due diligence with follow-up efforts (i.e., the patient or health care practitioner is unable to provide additional information, or 
the patient is lost to follow up). Serious AEs that occur more than 30 days after the last dose of 
study drug need not be reported unless the Investigator considers them related to study drug.
8.3.1.6. Sponsor Reporting Requirements
The Sponsor or its legal representative is responsible for notifying the relevant regulatory 
authorities of SAEs meeting the reporting criteri a. This protocol will use Appendix A of the 
current IB as the Reference Safety Document. The expectedness and reporting criteria of an SAE 
will be determined by the Sponsor fr om the Reference Safety Information.
8.3.1.7. Investigator Reporting Requirements
The Investigator must fulfill all local regulatory obligations required for the study Investigators. 
It is the Principal Investigatorâ€™s responsibility to notify the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) of all SAEs that occur at his or her site. Investigators will 
also be notified of all SUSAR events that occur during the clinical study. Each site is responsible 
for notifying its IRB/IEC of these additional SAEs.PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee 
reportineporti
urgentlurgent
ld be usld be 
)..
it the SAthe S
mmust bust mmm
e personperso
Once thence th
alert, walert, w
time thime 
are of anare of 
fter the ter th
nt resolvt reso
be obtaine obta
lth care th car
up). Seup). S
reportedeporte
or Repor Rep
or its legits le
of SAEf SA
Bas theas th
be determbe deter
8.3.1.7.3.1.7
TheThe
I
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 59of 106Invest igators will receive blinded informat ion unless unblinded informat ion is judged necessary 
for safet y reasons.
8.3.2. Exposure During Pregnancy and/or Lactation
TAK -935 shoul d not be adm inistered to pregnant and lactating females because the potential for 
adverse reactions to TAK -935 in pregnant females, fetuses, and nursing infants is unknown.
Pregnancy data will be collected during this study  for all  patients. Exposure during pregnancy 
(also referred to as exposure in -utero [EIU]) can be the result of either maternal exposure or 
transmissio n of drug product via semen fo llowing paternal  exposure.
For all Ovid products, both in development or post -approval, exposure during pregnancy must b e 
recorded and the patient fo llowed unt il the outcome of the pregnancy is known (spontaneous 
miscarri age, el ective terminat ion, normal birth, or congenital abnormalit y), even if the patient 
discontinues study  drug or di scont inues from the study .
If a patie nt within this study  or a pati entâ€™s partner beco mes pregnant while treated or exposed to 
study  drug, the Invest igator must submit a pregnancy form to Ovid via the same method as SAE
reporting. Pharmacovigilance will supply the Investigator with a copy  of aâ€œPregnancy Reporting 
and Outcom e Form /Breast Feeding.â€ When the outcome of the pregnancy  becomes known, the 
form shoul d be com pleted and returned to Ovid or Ovid Pharmacovigilance delegate. If
additional follow-up is requi red, the Invest igator will be requested to provi de the inform ation.
Exposure of an infant to an Ovid product during breastfeeding must also be reported and any  
AEs experienced by  the infant m ust be reported to Ovid Pharmacovigilance or designee via 
Email or fax ( Secti on 8.3.1.5 ).
Pregnancy is not regarded as an AE unless there is a suspicio n that study  drug may  have 
interfered wi th the effectiveness of a contraceptive medicat ion. However, complicat ions of 
pregnancy and abnorm al outcom es of pregnancy are AEs and may  meet cri teria for an SAE 
(such as ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or 
congenital ano maly). El ective abortions without complicat ions should not be reported as AEs.
8.3.3. Safety Monitoring
The Sponsorâ€™s Medical Monitor and/or Pharmacovigilance physician will mo nitor safet y data 
throughout the course of the study .
8.3.3.1. Reporting of Abnormal Liver Function Tests
If a patient is noted to have ALT or AST elevated >3 Ã— ULN o n 2 consecutive occasions, as 
specified in Secti on8.1.11 , the abnormalit y shoul d be recorded as an AE.
If a patient is noted to have ALT or AST >3 Ã— ULN and total bilirubin >2 Ã— ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on8.3.1.5 . The Invest igator must contact the Medical Monitor for discussio n of the 
relevant patientdetails and possible alternat ive etiologies, such as acute viral hepat itis A or B or 
other acute liver disease or medical history /concurrent m edical  condi tions. Fo llow
-up laboratory  
tests as described in Section8.1.11 must also be performed.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 60of 1068.4. Appropriateness of Measurements
All efficacy and safet y assessments included in this study  are generally regarded as reliable and 
accurate with respect to the ef ficacy and safet y assessments in individuals and populat ions with 
Dravet syndrome and LGS.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 61of 1069. DATA QUALITY ASSURAN CE
To ensure accurate, complete, and reliable data, the Sponsor or its representatives will do the 
following:
ï‚·Provi de instructi onal material to t he study sites, as appropriate
ï‚·Sponsor start -up training to instruct the Invest igators and study  coordinators. This 
training will give instruction on the protocol, the complet ion of the eCRFs, and study  
procedures
ï‚·Make periodic visits to the study  site
ï‚·Be available for consultation and stay  in contact wit h the study  site personnel  by
Email, telephone, and/or fax
ï‚·Review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion
ï‚·Conduct a qualit y review of the database
In addition, the Sponsor or its representatives will periodically  check a sample of the patient data 
recorded against source documents at the study  site. The study  may be audi ted by the Sponsor or 
its representatives, and/or regulatory  agencies at any  time. I nvestigators will be given notice 
before an audit occurs.
To ensure the safet y of parti cipants in the study , and to ensure accurate, complete, and reliable 
data, the Invest igator will keep records of laboratory  tests, clinical notes, and patient medical 
records in the patient files as original source documents for the study . If requested, the 
Invest igator will provide the sponsor, applicable regulatory  agencies, and applicable IRBs/IECs 
with direct access to ori ginal  source docum ents.
9.1. Data Collection and St orage
All clinical raw data will be recorded prompt ly, accurately, and legibly, either directly into the 
source document or indelibly on paper (e .g., ECG readings). When recorded electronically, case 
report forms will be electronically generated. All raw d ata will be preserved to maintain data 
integrity. The Invest igator or designee will assume the responsibilit y of ensuring the 
completeness, accuracy , and timeliness of the clinical data.
The el ectroni c data capture sy stem  is fully validated and Code of Fed eral Regulat ions Ti tle 21
Part 11 com pliant. The el ectroni c data capture sy stem  will maintain a co mplete audi t trail  of all 
data changes. At each scheduled mo nitoring visit, the Invest igator or designee will cooperate 
with the Sponsorâ€™s representative(s) f or the frequent review o f study  docum ents to ensure the 
accuracy  and com pleteness of the data capture system.
Electronic consistency checks and manual review will be used to identify any errors or 
inconsistencies in the data. This informat ion will be provi ded to the respective study  sites by 
means of electronic or manual queries.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 62of 106The Investigator or designee will prepare and maintain adequate and accurate study  docum ents
(medical records, ECGs, AE and concomitant medicat ion reporting, raw data collect ion forms)
designed to record all observations and other pertinent data for each patient receiving study  drug 
or placebo.
The Investigator will allow Sponsor representatives, contract designees, authorized regulatory  
authori ty inspectors, and the IRB/IEC to have direct access to all documents pertaining to the 
study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 63of 10610. STATISTICAL METHODS AND PLANNED ANALYSES
10.1. General Considerations
All statistical analyses will be performed using SASÂ®Version 9.3 or higher. All clinical study 
data will be presented in patient data listings. Data summaries will be presented for all endpoints 
and will include descriptive statistics (number of patients [n], mean, standard deviation [SD], 
first quartile [Q1], median, third quartile [Q3], minimum and maximum) for continuous 
variables, and frequency and percentage for categorical and ordinal variables. If there are
missing values, the number of missing will be presented, but without a percentage. For all 
analyses, â€˜Baselineâ€™ refers to the prospective 4-week Baseline Period.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described in the statistical analysis plan (SAP) which will be finalized and approved prior to database lock. 
Additional exploratory analyses of the data may be conducted as deemed appropriate.
10.2. Stratification by Seizure Type
At Visit 2, all eligible patients will be stratified by 2 categories: patients with Dravet syndrome with convulsive seizures, and patients with LGS with drop seizures to ensure balance of 
treatments within each stratum. Note that pa tients with both the minimum number of convulsive 
and drop seizures will be assigned to a stratum following the noted rules.
Patients with Dravet syndrome:
!46 eligible patients diagnosed with Dravet syndrome with â‰¥3 convulsive seizures per
28 days during the prospective Baseline period will be randomized into the Dravet syndrome stratum
Patients with LGS:
!80 eligible patients diagnosed with LGS with â‰¥4 drop seizures per 28 days during the 
prospective Baseline period will be randomized into the LGS stratum
If a patient does not meet any of these criteria, the patient will be considered a screen failure.
10.3. Determination of Sample Size
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usents 
D], , 
areare
 For allFor al
uire an auire an
e to the to the 
e changchan
pproved proved
s deemedeem
categoriatego
ith droph dro
nts with ts with
m fofollowllo
osed wised w
spectivepectiv
patpatieient
tive Basve Ba
s not m not m
keDeteDet
roperty of Taked
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 64of 10610.4. Analysis Sets
10.4.1. Modified Intent-to-Treat Analysis Set
All randomized patients who have received at least 1 dose of study drug and have been assessed 
for at least 1 day in the Treatment Period will be included in the modified intent-to-treat (mITT) 
analysis set. All mITT analyses will be based on each patientâ€™s randomized treatment 
assignment.
10.4.2. Efficacy Analysis Set
All mITT patients whose efficacy assessments are compliant with Protocol Amendment 2 w ill be 
included in the efficacy analysis set. Efficacy  analyses for primary and secondary efficacy 
endpoints will be based on the efficacy analysis set.  
Efficacy analyses will be based on each patientâ€™s
randomized treatment assignment.CCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetoo--TreTr
who hawho 
e Treate Tre
mITT anaTT an
EfficaEffic
ITT TT patpa
luded inuded
endpondpo ini
raerty ial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 65of 10610.4.3. Safety Analysis Set
All rando mized pat ients who take at least 1 dose of study  medicati on will  be included in the 
Safety Analysis Set. Safet y analyses will be based on the medication that was actually  
administered to each patient.
10.5. Demographics and Baseline Characteristics
Dem ographic characteri stics include age, gender, race, ethnicit y, and study  center. Baseline 
characterist ics include baseline body  weight, hei ght, and the rando mizat ion stratum. Summary  
statist ics by treatment group and overall will include counts and percentages for discrete 
variables, and means, SD, Q1, medians, Q3, minimum and maximum for continuous variables.
10.6. Patient Disposition
All patients who discont inue from the study  will be identified, and the extent of their 
participat ion in the study will be reported. If known, a reason for their discont inuat ion will be 
given.
Disposi tion data will be summarized and provided in patient list ings.
10.7. Concomitan t Medications and Non -Pharmacologic Therapies and
Procedures
Concomitant medicat ions will be coded using the World Health Organizat ion Drug Di ctionary 
(WHO -DD). A by -patient listing of conco mitant medi cations will include all medicat ions taken 
during the s tudy regardl ess of the timing for the start of the medicat ion. All medications started 
prior to the administration o f the study  drug will be included in the data but will be ident ified as 
prior in the list ing. Only the conco mitant m edication use will be su mmarized.
The number and percentage of patients who took at least 1 medicat ion during the double -blind 
period as well  as the number and percentage of patient s who took each ty pe of medicat ion will 
be presented for each treatment group. Medicat ions will be listed according to their WHO -DD 
anatomic therapeut ic chemical (ATC) class level 4 and preferred drug name wit hin ATC class 
level 4 by decreasing frequency  of incidence for all act ive treatment groups combined.
10.8. Treatment Compliance
Treatment compliance will be summarized by  treatment group over the entire treatment period. 
Com pliance rates duri ng the treatment period will be derived using the fo llowing form ula:
100*(Total number of tablets/mini -tablets di spensed â€“Total number of tablets/mini -tablets 
return ed) / (Expected number of tablets/mini -tablets)
Expected number of tablets/mini- tablets to be taken is based on the date of first study  medicat ion 
dose and the date of last study  medicat ion dose (ie, [date of last study  medicat ion dose â€“date of 
first study medicat ion dose] +1). Compliance rates will be presented for the safet y analysis set 
using summary  stati stics and percentage for the frequency distributions (0% to <20%, 20% to
40%, 40% to <60%, 60% to <80%, 80% to <100%, 100% to â‰¤120%) by treatment grou p and
overall.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 66of 10610.9. Efficacy Analyses
10.9.1. Primary Efficacy Analyses
For the pati ents randomized to the Dravet syndrome stratum ( â‰¥3 convulsive seizures per 
28days), convulsive seizure frequencies per 28 days for the 4 -week prospective Baseline Period
and the Mainte nance Period will be calculated.
For the pati ents randomized to the LGS stratum ( â‰¥4 drop seizures per 28 days), drop seizure 
frequencies per 28 day s for the 4 -week prospective Baseline Period andthe Maintenance Peri od 
will be calculated.
The seizure frequency per 28 days in a study  period will be calculated as
(# of seizures) / (# of days seizures were assessed) ï‚´28
For each patient, percent change fro m Baseline to the frequency  during Maintenance Period (per 
28 day s) will be calculated for the seizure t ype corresponding to the assigned stratum of that 
patient (convulsive for the Dravet and drop for the LGS stratum). Percent change fro m Baseline 
will be co mpared between TAK -935 and pl acebo using a Mann -Whit ney (Wilcoxon) test 
adjusting for Baseline seizure frequency and randomizat ion stratum.
The null hypothesis of no treatment difference will be tested at a two -sided 0.05 l evel of 
significance. The Mann -Whit ney est imator and the corresponding 95% confidence interval (CI) 
comparing TAK -935 wi th placebo will also be displ ayed.
10.9.2. Secondary Efficacy Analyses
For Dravet stratum, percent change in convulsive seizure frequency fro m Baseline to the 
frequency  of convulsive seizures during the Maintenance Period will be compared between 
TAK -935 and placebo using a Mann -Whit ney test adjusting for Baseline convulsive seizure 
frequency  and rando mizat ion stratum. For the LGS stratum, percent change in drop seizure
frequency  from Baseline to the frequency o f drop sei zures during the Maintenance Period will be 
compared betwee n TAK -935 and pl acebo using a Mann -Whit ney test adjust ing for Baseline drop 
seizure frequency. The Mann -Whitney estimator and the corresponding 95% CI comparing 
TAK -935 wi th placebo will  also be displayed.
The primary  efficacy  analysis will be repeated for the 20-week Treatment Period.
For the Dravet syndro me strata, the proportion of treatment responders based on â‰¥25% 
worsening, <25% and >1% worsening, no change (Worsening of 1% to Reduction of 1%) , 
â‰¥25% 
reducti on, â‰¥50% reducti on, â‰¥75% reducti on, and 100% reduction from Baseline in convulsive 
seizure frequency for the Maintenance Period will be summarized for TAK -935 and placebo. 
The 95% CIs for the difference of proportions will be displayed for each responder category. For 
theLGS stratum, the proportion of treatment responders based on â‰¥25% worsening, <25% and 
>1% worsening, no change (Worsening of 1% to Reduction o f 1%), â‰¥25% reduction, â‰¥50% 
reducti on, â‰¥75% reduction, and 100% reduction from Baseline in drop seizure frequency for the 
Maintenance Period will be summarized for TA K-935 and placebo; 95% CIs for the difference 
of proportions will  be di splayed for each responder category .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 67of 106Change in CGI-S/C responses of Investigator reported impression of efficacy and tolerability of
study drug and change in Care GI-C responses  of parent/family reported impression of efficacy 
and tolerability of study drug will be analyzed descriptively.
Correlation of seizure  frequency reduction and plasma 24 HC level will be explored.
Techniques for handling missing information with respect to reporting of seizures in the 
treatment period (Dose Optimization and Maintenance) will be specified in detail in the 
statist ical analysis plan ( SAP).
10.10. Safety Analyses
All safety analyses will be conducted based on the Safety Analysis Set.
Descriptive statistics will be used to summarize all safety endpoints by tr eatment group.
Two-sided 95% CIs will be presented where meaningful. Data summaries will be displayed for 
incidence of AEs, clinical laboratory variables, vital signs, body weight and height, ECG 
parameters, percent myoclonic- and atyp ical absence-free days, as well as changes in behavioral 
and adaptive functioning measures using VABS and sub-scales of ABC-C, as appropriate.
All data will be listed by patient.
10.10.1. Physical Examination, Vital Signs, and Other Physical Findings
Physical examinations (general appearance; skin; h ead, ear, eye, nose, and throat; neck; lymph 
node; chest; heart; abdominal cavity; limb; cen tral nervous system; a nd musculoskeletal) at 
Baseline will be summarized. Shifts from Bas eline to post-baseline st udy visits in each body 
system/site will be summarized by treatment group.
Vital signs (temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure), 
weight, and height will be summarized descriptiv ely at Baseline and all post-baseline study visits 
by treatment group. Change from Baseline to all post-baseline study visits also will be 
summarized descriptively by treatment group.
Data listings will be provided.CCI
Property of Takeda: For Non-Commercial Use Only aed on thed on 
ummarumm
nted wheed w
ratoryatory vyy
icc--andan
measuremeasu
d by patiby pa
sical Exsical E
aminataminat io
est; hearst; he
ne will ne wi
stemem/si/smmteii
ViVitaltaliiiisllrms of Use
weiwei
band Subject to the Applicable Term
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 68of 10610.10.2. Clinical Laboratory Tests
Changes from Baseline to study timepoints in clinical chemistry, hematology, and urinalysis 
results will be summarized descriptively. Each laboratory parameter will be classified as low, 
normal, or high relative to th e parameterâ€™s reference range. Laboratory abnorm alities for each 
treatment will also be summarized with shift tables. Listings of patients with abnormal results 
will be provided.
10.10.3. Adverse Events
The following definitions will be used for AEs:
!Treatment-emergent adverse event (TEAE): Any AE that starts or increases in 
severity during or after the first dose of study drug
!Treatment-emergent SAE: A TEAE that is serious
The incidence of TEAEs, discontinuations due to TEAEs, drug-related, serious, and severe
TEAEs will be summarized. All AEs will be coded using MedDRA and will be summarized by
SOC and PT and treatment group. D etailed listings of AEs, SAEs, IARs, related AEs, and 
discontinuations due to AEs will be provided.
10.11. Pharmacokinetic/Pharmacodynamic Analyses
10.12. Other Statistical Issues
10.12.1. Significance Levels
A primary endpoint is defined and will be tested at 0.05 level of significance.  
10.12.2. Missing or Invalid Data
Techniques for handling missing information with respect to reporting of seizures in the 
treatment period (Dose Optimization and Maintenance) will be specified in detail in the 
statist ical analysis plan ( SAP).CCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeases inases 
d, seriou, seri
A and wiand w
s, IARs, IAR
c Anal Ana
StatisStat
ignificagnifi
ryyenenyydpod
10.12.20.12.2
TecTec
tTakeNon-Commercial Use Only and 
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 69of 10610.13. Interim Analyses
Plasma concentrations o f TAK -935 in first 12 patients within each category o f aged â‰¥9 years and 
aged <9 y ears will be used to estimate PK parameters using the current populat ion PK model. If 
needed, the dose will be adjusted. The frequency of PK sample co llection may be changed based 
on resul ts of interim analysis.
Overall and by -stratum  futility and interim analyses may be performed. Enrollment may be 
stopped for 1 of the strata if the treatment effect is not sufficient ly strong. If one stratum is 
discontinued, then the remaining pat ients may be re -allocated to continuing stratum. Thresho lds 
for stopping enrollment will be pre -specified in the interim analysis plan .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 70of 10611. INFORMED CONSENT, ET HICAL REVIEW, AND 
REGULATORY CONSIDERA TIONS
All laboratory  specimens, evaluat ion forms, reports, and other records wi ll be ident ified in a 
manner designed to maintain patient confident iality. All records will be kept in a secure storage 
area wi th limited access. Clinical informat ion will not be released without the written permissio n 
of the pati ent and/or pati entâ€™s legal representative (i.e., parent or legal guardian ), except as 
necessary  for monitoring and audit ing by the sponsor, its designee, US Food and Drug 
Administrati on, Heal th Authori ties, Ethi cs Co mmittees, and/or IRBs. 
The Investigator and all emplo yees and cow orkers invo lved with this study  may not discl ose or 
use for any  purpose other than performance of the study  any data, record, or other unpublished, 
confident ial information disclo sed to those individuals for the purpose of the study . Prior wri tten 
agreem ent from the Sponsor or its designee must be obtained for the disclo sure of any said 
confident ial information to other parties.
11.1. Informed Consent
The Investigator is responsible for ensuring that the patient understands the potential risks and 
benefits of par ticipat ing in the study, including answering any questions the patient may have 
throughout the study  and sharing in a timely manner any  new informat ion that m ay be rel evant to 
the pati entâ€™s willingness to continue his or her participat ion in the study .
TheICF will be used to explain the potential risks and benefits of study  parti cipat ion to the 
patient in simple terms before the patient is entered into the study , and to docum ent that the 
patient is sat isfied with his or her understanding of the risks and b enefi ts of parti cipat ing in the 
study  and desires to parti cipate in the study .
The Investigator is responsible for ensuring that informed consent is given by each patient or
legal representative. This includes obtaining the appropriate signatures and dates on the ICF prior 
to the performance of any protocol procedures and prior to the administration of study  drug.
A legal representative must give informed consent for a child to participate in this study. In 
addition to inform ed consent given by the legal re presentative, the child may  be requi red to give 
docum ented assent, if capable.
11.2. Data Monitoring Committee
The specific responsibilit ies of the iDMC are described in the DMC Charter, which is maintained 
as a separate document.
11.3. Ethical Review
The Sponsor or its representatives must approve all ICFs before they are used at investigative 
sites(s). All  ICFs must be com pliant wi th the ICH gui deline on GCP.
Docum entati on of  IRB/IEC approval  of the protocol  and the ICF m ust be provi ded to the 
Sponsor before the study may begin at the invest igative site(s). The IRB/IEC(s) will review the 
protocol  as requi red.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 71of 106The study  siteâ€™s IRB/IEC(s) should also be provided with the following:
ï‚·The current IB and updates during the study
ï‚·ICF
ï‚·Relevant curricula vitae
11.4. Regulatory Cons iderations
This study  will be conducted in accordance wit h:
ï‚·Consensus ethics principles derived fro m internat ional ethics guidelines, including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences (CIOMS) Internationa l Ethical Guidelines
ï‚·The ICH GCP Guideline (E6)
ï‚·Applicable laws and regulations
The Investigator or designee will pro mptly submit the protocol to applicable IRB/IEC(s). Some 
of the obli gations of  the Sponsor may  be assigned to a Third -Party  Organizat ion.
An identificat ion code assigned to each patient will be used in lieu of the patientâ€™s name to 
protect the patientâ€™s identit y when reporting AEs and/or other study -related data.
11.4.1. Confidentiality
The Sponsor affirms that subjectâ€™s rights to protectio n against invasio n of privacy are in 
compliance wi th ICH and other l ocal regul ations (whichever i s most stringent). Inform ation 
about pati ents and their records will be kept confident ial by the Sponsor and its representatives. 
Study  related records i dentifying patients will be kept confident ial and, to the extent permitted by  
applicable laws and/or regulat ions will not be made publicly available. 
All laboratory  specimens, evaluat ion forms, reports, and other records will be ident ified in a 
manner designed to maintain subject confident iality. All records will  be kept in a secure storage 
area wi th limited access. Clinical informat ion will not be released without the written permissio n 
of the pati ent and/or patient's custodi al parent or guardi an, except as necessary  for monitoring 
and audit ing by the sponsor, its designee, FDA, Health Authorit ies, Ethics Co mmittees, and/or 
IRBs.
The Investigator and all emplo yees and coworkers invo lved with this study  may no t disclose or 
use for any  purpose other than performance of the study  any data, record, or other unpublished, 
confident ial information disclo sed to those individuals for the purpose of the study . Prior wri tten 
agreem ent from the Sponsor or its designee mus t be obtained for the disclo sure of any said 
confident ial information to other parties.
If any o f the resul ts of the study  are published, patientâ€™s ident ity will remain confident ial.
The Sponsor requires the Invest igator to permit sponsor representatives a nd, when necessary , 
representatives from FDA and other regulatory  authori ties, m onitor, audi tor, IRB to have access 
to study  related m edical records in accordance wit h local privacy laws.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 72of 10611.4.2. Investigator Information
Physicians with a specialt y in neuro logy and/or epilepsy  disorders will  parti cipate as
investi gators in this clinical study .
11.4.3. Protocol Signatures
The Sponsorâ€™s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describ es the pl anned design and conduct of the 
study .
After reading the protocol, each Principal Invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Sponsor representative.
11.4.4. Final Report Signature
The clinical study  report Coordi nating Invest igator will sign the final clinical study report for this 
study , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
The Sponsorâ€™s responsible medical offic er and statist ician will approve the final clinical study  
report for this study , confi rming that, to the best of his or her knowledge, the report accurately  
describes the conduct and results of the study .
11.5. Publication Policy
The full terms regarding publicat ion of the results of this study  are outlined in the Clinical Study  
Agreement, Statement of Agreement, or the Master Clinical Study  Agreement. Publicat ion is 
permitted only after mult i-center results are available and all disclo sure requi rements fo r clinical 
study  registries have been met. Any data to be submitted for publicat ion, including abstract 
submissio ns or presentations, are required to be submitted to Ovid for review at least 30 day s 
prior to submissio n.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 73of 10612. LIST OF REFERENCES
1.Howi e S. Bl ood sa mple vo lumes in child health research: review of safe limit s. Bullet in 
of the Worl d Heal th Organizat ion, 2011;89:46- 53. doi : 10.2471/BLT.10.080010.
2.Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: 
Reco mmendat ions of the 2012 I nternational Tuberous Sclerosis Co mplex Consensus 
Conference. Pediatr Neurol. 2013;49(4):243 -54.
3.Paul SM, Doherty  JJ, Robi chaud AJ, Belfort GM, Chow BY, Hammond RS, et al. The 
major brain cholesterol metabo lite 24(S) -hydroxycho lesterol  is a potent alloster ic 
modulator of N -methyl-D- aspartate receptors. J Neurosci 2013;33(44):17290 -300.
4.Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al.
Revised termino logy and concepts for organizat ion of seizures and epilepsies: report of 
the ILAE Commissio n on Classificat ion and Termino logy, 2005 -2009. Epilepsia
2010;51(4):676 -85.
5.Scheffer IE, Berkovic S, Capovilla G, Conno lly MB, French J, Guilhoto L, et al. ILAE 
classificat ion of the epilepsies: Position paper of the ILAE Commissio n for Class ificat ion 
and Termino logy. Epilepsia 2017;58(4):512 -21.
6.Wagner T, Tsai M, et al. Clinical trial simulat ions using a pharmacokinetic/enzyme 
occupancy/pharmacodynamic model of TAK -935, a cho lesterol 24S -hydroxylase 
inhibitor; poster presented at the American Epilepsy  Society  71 st Annual  Meeting 
(Washington, D.C. 2017).
7.Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational 
classificat ion of seizure ty pes by the Internat ional League Against Epilepsy : Posi tion 
Paper of the ILAE Co mmissio n for Classificati on and Termino logy. Epilepsia 2017.
8.Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia -Suicide Severit y Rating Scale: init ial validit y and internal  consistency findings 
from three m ultisite studi eswith adolescents and adults. Am J Psychiatry
2011;168(12):1266 -77.
9.Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a 
behavior rating scale for the assessment of treatment effects. Am J Ment Defic
1985;89(5):485 -91.
10.de Bildt A, Kr aijer D, Sy tema S, Minderaa R. The Psy chometric Properties of the 
Vineland Adapt ive Behavior Scales in Children and Adolescents with Mental 
Retardation. J Aut ism Dev Disord. 2005;35(1):53 -62.
11.Bretillo n L, Lutjohann D, Stahle L, Widhe T, Bindl L, Eggertsen G, et al . Plasma levels 
of 24S-hydroxy cholesterol  reflect the balance between cerebral production and hepat ic 
metabo lism and are inversely related to body  surface. J Li pid Res 2000;41(5):840 -5.
12.Cartagena CM, Ahmed F, Burns MP, Pajoohesh -Ganji  A, Pak DT, Fa den AI, et al.
Corti cal injury  increases chol esterol  24S hy droxylase (Cy p46) levels in the rat brain. J 
Neurotraum a 2008;25(9):1087-98.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 74of 10613.Tian G, Kong Q, Lai L, Ray -Chaudhury  A, Lin CG. Increased expressio n of cho lesterol
24S- hydroxylase results in disruptio n of glial glutamate transporter EAAT2 associat ion 
with lipid rafts: a potential role in Alzheimer's disease. J Neurochem 2010;113(4):978 -89.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 75of 106APPENDIX 1.SCHEDULE OF ASSESSME NTS
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 76of 106
CONFIDENTIALTable 3 Schedule of Assessments
Screening/ 
Baseline 
PeriodDouble-blind Treatment PeriodFollow-
up
PeriodRand/
Dosing
Day
Visit (V) or Phone Call (P) 
NumberkV1 V2 P1 V3 P2 V4 P3 V5 P4 V6 V7
Study Day Days -42 to -1 Day 1aDay 8a,l/
phone 
callDay 15aDay 22l/
phone 
callDay 36 Day 57l/
phone 
callDay 85 Day 113l/
phone 
callDay 141/ 
ETa,b,dDay 169/
Follow-
upc
Visit Window (days) Â±2 Â±2 Â±2 +2 Â±7 +2 Â±7 +2 Â±7 -7
Informed consent and assent 
(if applicable)X
Inclusion/exclusion criteria X X
Randomization X
Demographics, medical 
history, medication historyX
Height, weight X X X X X X
Concurrent medical 
conditionsX X
Concomitant medications X X X X X X X X X X X
CGI-S/C & Care GI-CjXX X X
C-SSRS X X X X
Vineland Adaptive 
Behavioral Scale (VABS)X X
Aberrant behavior checklist 
(ABC-C)X X
Quality of Life in Childhood 
EpilepsyXX
Sleep Disruption Numerical 
Rating ScaleXX
Exit surveyjX
Serum/urine pregnancy testeXX X
Vital signs X X X X X X X
Physical examination X X XfXfXX
Neurological examination, 
 XX X X X X X
12-lead ECGnXX X XCCI
Property of TakedXXda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useherapeuherape
fU
ermTe
bl
V5V5ca
A/
one e 
callcallDayDaAAAppA
+2+2thtoct
bjeub
dddSndannn
ly
OXeOeOeOeO
Useeee
lUiciciciarci
me
omC
XXn
rN
FoFoFoFoFo
XXa:ed
Xke
ofooo
rtyo
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 77of 106
CONFIDENTIALScreening/ 
Baseline 
PeriodDouble-blind Treatment PeriodFollow-
up
PeriodRand/
Dosing
Day
Visit (V) or Phone Call (P) Number
kV1 V2 P1 V3 P2 V4 P3 V5 P4 V6 V7
Study Day Days -42 to -1 Day 1aDay 8a,l/
phone 
callDay 15aDay 22l/
phone 
callDay 36 Day 57l/
phone 
callDay 85 Day 113l/
phone 
callDay 141/ 
ETa,b,dDay 169/
Follow-
upc
Visit Window (days) Â±2 Â±2 Â±2 +2 Â±7 +2 Â±7 +2 Â±7 -7
Clinical laboratory tests (Chemistry, hematology, and urine analysis)XX X X X X
Distribute seizure diary and 
provide instructions on useXX X X X X
Collect seizure diary data X X X X X X
Plasma samp le for TAK-935 
PKgXXX X X
Plasma sample for AED analysisXX X
Plasma sample for PD 
(plasma 24HC)hXXX X X X
IWRS to obtain patient ID/medicationID/patient statusXX X X X X X
Dispense study drug X X X X Xm
In-clinic administration of 
morning dose of study drugXXX X X
Study drug return/
accountability/complianceXXX X X
Adverse Events X X X X X X X X X X
Abbreviations: AED=antiepileptic drug; Care GI-C=Caregiver Global Impression of Change; CGI-S/=Clinicianâ€™s Clinical Global Impr ession of Severity and 
Change; C-SSRS=Columbia Suicide Severity Rating Scale; ECG=elect rocardiogram; ET=Early Termination; ID=identification; IWRS=int eractive web 
response system; P=phone call; PD=pharmacodynamics; Rand=randomization; V=visit.
a Two days after each dose escalation or taper, patients will be contacted by phone to monitor study drug compliance, concomitan t medication use, and AEs. 
Patients will be contacted by phone within first two days following escalation to the maximum dose to assess safety and tolerab ility of the study drug.
b Patients who do not continue into the open-label extension (OLE) study will undergo the dose taper procedures and will then pro ceed to the Follow-up Period.
Patients who continue in OLE may do a combined visit, i.e., the last visit of this trial may be combined with the first visit of  the OLE
c The timing of the Follow-up Period and Follow-up Visit will depend on the dose taper procedures followed. Patients who are on Dose 1 (the lowest 
administered dose) of TAK-935 during the Maintenance Period will not undergo dose taper. Visit may be eliminated for patients e nrolled in OLE.CCI
Property of Takeda: For Non-Commercial UXXU
rcierrr
mm
CCCCoC
XXNonNre GIe G-C=C
everity Rverity
pharmapharm
ion or tapon or t
phone wihone 
ue into thue into 
n OLE mOLE 
lowow--up Pup
) of TAKof TAe Only and Subject to the Applicable Terms of Useherapeuherape
fUo
msssss
PeTbl
Day 85Day 85abbb
Ab
AAApA
he
tttttct
XXbje
XSu
ndndndndnd
ly
eOeOeOeO
Use O
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 78of 106
CONFIDENTIALd Patients who withdraw early from the study should complete all Final Visit procedures at the ET Visit.
e For sexually active female patients of childbearing potential, a serum pregnancy (hCG) test will be performed at the Screening  visit. If urine cannot be collected 
at Visit 2, the reason should be documented in the source document, the results of the serum pregnancy test obtained at Visit 1 must be confirmed to be 
negative by the Investigator prior to randomization, and the results of a serum pregnancy test at Visit 2 must be confirmed to be negative before the patient can 
receive the first dose of study drug. Additional pregnancy tests (serum or urine) may be performed throughout the study at the Investigatorâ€™s discretion.
f Physical examination can be limited to general appearance; head, eyes, ears, nose, and throat [HEENT]; cardiovascular; respirat ory, and abdominal at Day 15 
and Day 85.
g For the first 12 randomized patients aged â‰¥9 years and 12 randomized patients aged <9 year s, PK blood samples for measurement of TAK-935 and M-I 
concentrations in plasma will be collected within 1 hour before the morning dose (pre-morning dose) and 30 min (Â±10 min) and 1, 2 , and 4 hours (Â± 10 min) 
after the morning dose at Visit 2 (Day 1); within 1 hour before th e morning dose (pre-morning dose) and 30 min (Â±10 min) post-dose a t Visits 3, 4, 5, and 6. In 
the remaining randomized patients, PK blood draws will occur within 1 hour before the morning dose (pre-dose) and 30 min (Â±10 min) post-morning dose at 
Visits 2, 3, 4, 5, and 6 (Days 1, 15, 36, 85, and 141, respectively) during the study. An intravenous line (IV) line may be insert ed for collection of all blood 
samples during the visit.
h PD blood samples for measurement of 24HC levels in plasma will be collected at pre-morning dose on Visits 2, 4, 5, and 6 (Days 1, 36, 85, 141, and 169,
respectively).
i  
j The ET/Exit survey will be conducted at Visit 6.k Based on local country regulations and Sponsor approval, some study visits may be conducted at home.
l The study visits on Days 8, 22, 57, and 113 (phone calls 1 through 4) will be conducted via telephone.
m At Visit 6 (Day 141), dispensing study drug is applicable only for patients not entering the Open-label Extension study.n A 12-lead ECG will be recorded at Screening (Visit 1) and at 30 min (Â±10 min) after the morning dose at Visits 2, 4, and 6.CCI
Property of Takeda: For Non-Commercial Use Only and Sconductconduc
nducted vducted ubject to the Applicable Terms of Useherapeuherape
fU
sit. t. If urinIf ur
must be must b
o be negabe n
at the Invat the I
ar; respira; resp
for meafor me
min (in (Â±Â±1010
0 minmin(Â±
pre-e-dosedos)
ne (IV) le (IV
dose on dose on
ot enterinot enter
min) aftein) afdS u b
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 79of 106APPENDIX 2.STUDY TAK -935-2002 (OV935) : CLINICAL 
LABORATORY TESTS
Hematology Serum Chemistry Urinalysis (a) Study Specific
RBC ALT pH Plasma
WBC with 
differential
(% and absolute)Albumin Specific gravity 24HC
Hemoglobin Alpha -1-acid 
glycoproteinProtein
Hematocrit Alkaline phosphatase Glucose
Platelets AST Blood Plasma (Concomitant AEDs)
PT/INR Total bilirubin Nitrite Carbamazepine
aPTT Total protein Clobazam
Creatinine N-desmethylclobazam
Blood urea nitrogen Microscopic Analysis: (b) Valproic acid
Creatine kinase RBC/high power field Phenytoin
GGT WBC/high power field Topiramate
Potassium Epithelial cells, casts etc. Lamotrigine
Sodium Rufinamide
Glucose Zonizamide
Chloride Phenobarbital
Bicarbonate Levetiracetam
Calcium Lacosamide
Total cholesterol 10-hydroxycabazepine 
(metabolite
HDL cholesterol of oxcarbazepine)
LDL cholesterol Trileptal
Triglycerides Epidiolex
Diagnostic Screening
Serum Urine (a)
hCG (for pregnancy) (c) hCG (for pregnancy) (c)
Abbreviations: AED= antiepileptic drug; aPTT= activated partial thromboplastin time, GGT=Î³ -glutamyl transferase, 
HDL=high -density  lipoprotein, LDL=low -density  lipoprotein, PT=prothrombin time, RBC=red blood cell; WBC=white blood 
cell.
(a) If urine cannot be collected at the time of the Screening Visit or other Visits due to the patientâ€™s cooperation or becau se the 
patient is wearing a diaper, it is acceptable fo r the patient to continue in the study and the reason should be documented in the 
source document.
(b) Only if dipstick results are positive.
(c) Only for sexually active female patients of childbearing potential. If urine cannot be collected at Visit 2, t he reason should be 
documented in the source document ,the results of the serum pregnancy test obtained at Visit 1 must be confirmed to be 
negative by the Investigator prior to randomization, and results of a serum pregnancy test at Visit 2 must be confirm ed to be 
negative before the patient can receive the first dose of study drug . An additional serum hCG pregnancy test will be performed 
at the Final Visit.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 80of 106APPENDIX 3.STUDY TAK -935-2002 (OV935) : SAMPLING 
SUMMARY
This table summarizes the maximum number of samples and vol umes f or all sampling and tests 
during the study . Fewer samples may  be taken, but this will not require a protocol amendment.
Protocol TAK -935-2002: Sampling Summary for Patients Weighing â‰¥10 kg 
Purpose Sample 
TypeMaximum 
Amount per 
SamplebMaximu m 
Number 
SamplesMaximum 
Volume in 
30-day PeriodMaximum 
Total 
Amount
Standard laboratory testsaBlood 5.7 mL 6 11.4 34.2 mL
Pharmacokinetic samples Blood 1 mL 13 7 13 mL
AED Drug concentration Blood 4 mL 3 4 12 mL
Plasma Biomarker (24HC 
)samples (PD)Blood 2 mL 6 4 12 mL
Optional blood sample for 
researchBlood 2 mL 1 2 2 mL
Total Blood 14.7 mL 41 mL 28.4 mL 73.2 mL
aAdditional samples may be drawn if needed for safety purposes.
bMaximum volume per sample is 14.7 mL.
Howie SR. Blood sample volumes in child health research: review of safe limits. Bulletin of the World Health Organization. 
2011;89(1):46 -53. doi:10.2471/BLT.10.080010.
Blood Collection: Priority Order
ï‚·Coagulation
ï‚·Chemistry
ï‚·Pregnancy test
ï‚·Serum sample for AED analysis
ï‚·Hematology
ï‚·Plasma sample for TAK -935 PK
ï‚·Plasma sample for PD (plasma 24HC)
Optional blood sam ple for research analysis :Blood vol ume limit ations will som etimes preclude 
the collect ion of all samples in a particular study  visit. In case this happens, for bl ood sam ple 
analysis , safety  labs shoul d be pri oritized over labs for efficacy and exploratory  analyses.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 81of 106APPENDIX 4.STRONG CYP3A4 INDUCE RS AND INHIBITORS
Use of perampanel fro m screening through fo llow-up is prohibited.
The strong inducers and inhibitors of CYP 3A4 listed below also are prohibited:
Strong CYP3A4 INDUCERS Strong CYP3A4 INHIBITORS
Bosentan Clarithromycin
Efavirenz Telithromycin
Etravirine Nefazodone
Modafinil Itraconazole
Nafcillin Ketoconazole
Nevirapine Following antivirals: atazanavir, darunavir, indinavir, 
lopinavir, nelfinavir, ritonavir, saquinavir, and 
tipranavir.Rifampin
Rifabutin
St. Johnâ€™s Wort
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 82of 106APPENDIX 5.OVERVIEW OF MAJOR CH ANGES 
IMPLEMENTED BY AMENDMENT S
AMENDMENT 2
1. Clarified that iDMC will review the AE profile sof the first 12 patients aged
â‰¥9years completing 4 weeks of treatment
Description of Change :The iDMC will review the AE profile sof the first 12 patients 
(previously  first 20) a ged â‰¥9years completing 4 weeks of treatment priorto reco mmending
treatmentf
or pa tients ag ed <9 years
Rationale for Change :iDMC has reviewed the data of patients aged â‰¥9 years fro m another 
study  (TAK -935-18-002) who were treated with TAK- 935, and iDMC have approved to 
initiate treatment of patients aged 2
-9 years ol d in the study . As TAK -935 i s deemed safe in 
patients aged â‰¥9 years in TAK -935-18- 002, i t will  be appropri ate to decrease the number of 
patients aged â‰¥9 years needed before init iation treatment of 2
-9 years ol d pat ients. 
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 5.1
2. Renamed the Titration Period to the Dose Optimization Period and increased the 
period duration from 2weeks to 8weeks
Description of Change :Changed the period during which patients will t itrate to the optimal 
dose from 2weeks to 8weeks in order to allo w for 6 weeks of dose optimization . This 
revisio n resulted in a change inthe Treatm ent Period from  14weeks to 20weeks. Updated 
Figure 1 to reflect the name change and the extension of the Dose Optimizat ion Period. 
Updated the Schedule of Assessments to reflect the increase in the number of days on study . 
Updated the total duration o f the study  to approximately 30 weeks.
Rationale for Change :To allow for an addit ional 6weeks to adjust patient dosing to opti mal 
levels after the m aximum  dose had been reached , based on Invest igator judgment and with 
approval  of the Medical Monitor . 
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 5.1
ï‚·Figure 1
ï‚·Secti on 7.2
ï‚·Secti on 10.9.2
ï‚·Secti on 10. 12.2
ï‚·Appendix 1 (Table 3)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 83of 1063 Added additional phone calls to monitor dose optimization and safety
Description of Change :Phone calls were added due to the increase in the duration o f the 
Dose Optimizat ion Peri od (f ormerly Titration Period) to 6 weeks. Updated the Schedule of 
Assessments to reflect the increase in the number of days on study . Phone calls will be made 
at Day s 8, 22, 57, and 113. Clinic visit swill occur at Screening (Visit 1), Day 1 (Vi sit 2), 
Day 15 (Vi sit 3), Day  36 (Visit 4), Day  85 (V isit 5), Day  141 (Vi sit 6), and Day 169 (Vi sit 7; 
follow-up).
Rationale for Change :To allow for an addit ional 6 weeks to adjust patient dosing to optimal 
and to m onitor saf etyand com pliance . 
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 5.1 (Fi gure 1)
ï‚·Secti on 7.2
ï‚·Appendix 1 (Table 3 )
4. Removed hepatitis B and C serology panel
Description of Change : Removed clinical laboratory  tests for hepatitis B and C, including an 
additional blood sam ple for HCV qPCR for pati ents who are posit ive for hepat itis C Ab. 
Removed from exclusio n criterion #7 that pati ents who are posit ive for hepat itis C Ab are 
eligible if they  have a negat ive hepat itis C viral load by qPCR. 
Rationale for Change : There i s no need to acti vely screen for hepat itis B and C .
Sections Impacted :
ï‚·Synops is
ï‚·Secti on 6.2
ï‚·Appendix 2
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 84of 1065. Changed the follow -up visit from a phone call to a clinic visit
Description of Change : The Follow -up P eriod previously consisted of a phone call with the 
option to have fo llow-up assessment performed at the clinic. This Follow-up V isit is now a 
clinic visit with final assessments forconcomitant medicat ions, vital signs, physical 
examinat ion, neuro logical examinat ion, collect ion of seizure diary, plasma sample for 24HC, 
IWRS for pati ent status , study  drug accountabilit y, and AEs.
Rationale for Change : Because this amendment added an assessment of 24HC at the 
Follow-up Vi sit, it is necessary  for pati ents to vi sit the clinic to have samples obtained for 
24HC. Addit ionally, the patient can return any  unused study  drug to the s ite. 
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 7.2 
ï‚·Appendix 1 (Table 3)
6. Revised the PK collection timepoints and added sampling windows
Description of Change : The PK collect ion text was revised as fo llows: 
Pharmacokinet ic (PK) sample collection will start at Visit 2 (Day  1), and i t is designed to 
investigate the PK in all pat ients. The first 16 12 rando mized pat ients aged â‰¥9 years and the 
first 16 12 randomized patients aged <9 years will receive the first d ose of  TAK -935 or 
placebo in the clinic; PK blood draws will occur within 1 hour before the morning dose ( pre-
morning -dose) and 30 min (Â±10 min) and 1, 2, and 4 3, and 5 hours (Â±10 min) after the first
morning dose. After Vi sit 2 (Day  1), addi tional PK sam ples will  be collected within 1 hour 
before themorning dose (pre-morning -dose)and 30min (Â±10 min) post-morning -dose (1 to 5
hours after the dose) at Visit s3, 4, 5, and 6 7 4, 5, 6, and 7 during the study.
The rem aining rando mized pat ients in the study  will receive the first dose of TAK -935 or 
placebo in the clinic, with PK blood draws occurring within 1 hour before the morning dose
(pre-dose)and 30min (Â±10 min) one draw post-dose (1 to 5 hours after the d ose) at Visits2, 3, 
4, 5, and 6 4, 5, 6, and 7 during the study.
Rationale for Change :No window was previously provided in the protocol; adding a window 
grants flexibilit y to the si tes in collect ion of this sample. The phrase â€œwit hin 1 hour before 
doseâ€ was not previously consistent throughout the protocol. Adjusted the visit days to reflect 
new schedule of phone calls and visits. The PK sampling times were changed to better capture 
the PK profile and when C maxis reached.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 8.1.22.1
ï‚·Secti on 10.13
ï‚·Appendix 1 (Table 3 )
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 85of 1067. Added concomitant medications that should not be altered during study or that 
require approval
Description of Change :  Medical marijuana and cannabidio l products were added to the list 
of concomitant m edicat ions that should not be altered during the study. Added that use of 
traditional Chinese medicines should be approved by  the Medical  Moni tor at screening.
Rationale for Change :Medi cal marijuana and cannabidio ls are used as ant iepileptic drugs 
and, therefore, like other AEDs, they  shoul d not be al tered during the study. Tradit ional 
Chinese medicine may include a number of chemical co mponents that may potentially have a 
drug-drug interaction wit h TAK -935 and ,therefore ,must be approved by the Medical 
Moni tor.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 7.6
8. A dded perampanel as prohibited concomitant medication
Description of Change : Use of perampanel fro m screening through fo llow-up is prohibited.
Rationale for Change :The new data fro m the TAK -935-2001 (OV935) study in adult 
patients wi th epilepti c encephal opathy  indicated that there is a potential drug -drug interaction 
between TAK -935 and perampanel, which may  compromise the efficacy  of TAK -
935.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 7.6
ï‚·Appendix 4
9. Updated the approximate total blood volume collected
Description of Change : The approximately total blood vol ume collect edfrom each patient 
over the course of the study  was revised from  69 to 7 3.2mL.
Rationale for Change :Revised b ased on changes in the Schedule of Assessment s (Table 3)
and central  laboratory  requi rements.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 8.1.11
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 86of 10610. Revised the primary objective
Description of Change : The primary object ive was revised as fo llows:
To investigate the effect on the frequ ency of all seizures (convulsive and drop) in pat ients 
treated with TAK -935 as an adjunct ive therapy compared to placebo at the end of the 
Treatment Period (Titration plus in the Maintenance Periodperiods)
Rationale for Change : The preliminary data from the TAK -935-2001 (OV935) study  in adult 
patients wi th epilepti c encephal opathy  indicate that full effects of TAK -935 are observed after 
8 weeks of treatment. Accordingly , to observe the full efficacy  effects, the primary  endpoint 
waschanged to the last 12 weeks of treatment, which is the Maintenance Period.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 4.1.1
11. Revised the secondary objectives
Description of Change : The secondary objective for comparing patients treated with 
TAK -935 as an adjunct ive therapy to placebo for the frequency o f all seizures (convulsive and 
drop) was revised fro m throughout the Maintenance Period to throughout the Treatment 
Period.
The secondary  objective for com paring patients treated wi th TAK -935 as an adjunct ive 
therapy  to pl acebo forthe frequency  of convulsive seizure in patients with Dravet Syndrome, 
the frequency o f drop sei zure in pat ients with LGS, the frequency o f patients considered 
treatm ent responders in pat ients with LGS, and the frequency of pat ients considered treatment 
responders with Dravet Syndrome was revised from through the Treatment Period to the 
Maintenance Period.
The PK secondary  object ive was revised as fo llows:
To characterize the relationship between the PK and plasma 24HC levels and s eizure 
frequency
The fo llowing secondary  objective was deleted:
To investigate changes in plasma concentrations of concomitant AEDs and their 
pharmaco logically act ive metabolites in pat ients treated with TAK -935 as an 
adjunctive therapy
Rationale for Change : Secondary  objectiveswere revised to be consistent with the primary 
objective and to evaluate the changes in seizure frequency that may potentially occur earlier, 
i.e., during the ent ire treatm entperiod . The rel ationship between the plasma 24HC levels and 
seizure frequency was deemed to be more clinically meaningful.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 4.1.2
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 87of 10613. Updated language regarding patientâ€™s legal representative
Description of Change : Changed â€œpatientâ€™s custodial parent or guardianâ€ to â€œpatientâ€™s legal 
representative (i.e., parent or legal guardian).â€
Rationale for Change : For consistency throughout the document.
Sections Impacted :
!Synopsis
!Section 6.1
!Section 6.3.1
!Section 7.2
!Section 11CCI
Property of Takeda: For Non-Commercial Upatientpatien
â€œpatienâ€œpatie
gal guaral gu
r consisr cons
n 6.16.1
ctiion 6.on 6
SectiSect
!!Ss of Uses
tyUse Only and Subject to the Applicable Terms
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 88of 10614. Clarified definition of benzodiazepines as AEDs
Description of Change :Added text to inclusio n criterion #5 to state that benzodiazepines 
used chronically (on daily  frequency) to treat seizures are considered AEDs .
Rationale for Change :For cl arificat ion and based on feedback fro m the clinical sites.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 6.1
15. Clarified diagnosis of Dravet syndrome and Lennox -Gastaut syndrome for 
inclusion
Description of Change :Revised the text of inclusio n criterion #11 to update the symptoms 
that support the diagnosis o f Dravet syndrome and LGS for inclusio n in this study .
Rationale for Change :Based on guidelines fro m the Epilepsy  Consorti um;clarificat ion is 
provi ded to enhance diagnosis of Dravet Syndrome and LGS.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 6.1
16. Clarified that convulsive status epilepticus requiring hospitalization is an 
exclusion criterion for this study
Description of Change :Revised exclusio n criterion #1 to state that patients that have been 
admitted to a medical facilit y and intubated for treatment of status epilept icus 2 or m ore times 
in the 3 months immediately prior to the screening visit will be excluded fro m the study .
Rationale for Change :Status epilept icus can be a long seizure over 5 minutes and several 
patients, especially wit h Dravet Syndrome, can have prolonged seizures (>5 minutes) that are 
not severe enough to exclude them from the study . Therefore, pati ents whose status epilept icus 
requi red hospi talizati on and intubati on will  be excluded.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 6.2
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 89of 10618. Added malignancy (including progressive tumors) as an exclusionary condition
Description of Change : Added to exclusion criterion #4 that malignancy (including 
progressive tumors) would be an exclusi onary unstable clinically significant condition
Rationale for Change : Based on unpredictable effects on efficacy and that progressive 
tumors have poor prognosis.
Sections Impacted :
!Synopsis
!Section 6.2
19. Clarified the duration for avoidance of pregnancy and donation of ova and sperm 
for female and male patients, respectively
Description of Change : Added text to clarify that avoidance of pregnancy and donation of 
ova and sperm should be up to 90 days (previous ly 30 days) after the last dose of study drug.
Rationale for Change : The original text was not consistent with other sections of the 
protocol.
Sections Impacted :
!Section 10.1.12CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applionary onary
ncyncy(inc(iyy
gnificangnifica
acy andcy anpp
ce of pre of p
espectivspecti
to clario cla
days days (p(
original rigina
1.12.12O
Fos of Usess
plicable Terms
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 90of 10619. Revised the primary endpoint
Description of Change :Changed the primary endpoint from percent change fro m Baseline in 
seizure frequency during the Treatment Period to percent change fro m Baseline in seizure 
frequency  during the Maintenance Period. 
Rationale for Change :The preliminary data from the TAK -935-2001 (OV935) study in adult 
patients wi th epilepti c encephal opathy  may indicate that full effects of TAK -935 are observed 
after 8 weeks of treatment. Accordingly, because treatm ent durati on is extended to 20 weeks 
and to observe the full effects, the prim ary endpoint was changed to the last 12 weeks of 
treatm ent, whi ch is the Maintenance Period.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 4.2.1
ï‚·Secti on 10.9. 1
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 91of 10620. Revised the secondary endpoints
Description of Change : The secondary  endpoint for percent change fro mBaseline in seizure 
frequency  per 28 days (convulsive and drop) was revised from during the Maintenance Peri od 
to during the Treatment Period.
The secondary  endpoints for percent change fro m Baseline frequency o f convulsive seizure in 
patients wi th Dravet Syndrome andthe frequency  of drop sei zure in pat ients with LGS was 
revised fro m during the Treatm ent Peri od to during the Maintenance Period, and the 
proporti on of  patients with LGS considered treat ment responders in patients and pat ients with 
Dravet Syndro me considered treatment responders was revised fro m during the Treatment 
Period to during the Maintenance Period. 
The PK secondary  endpo intwas revised as fo llows:
Correl ation ofTAK -935 concentra tion and plasma 24HC levels withseizure frequency
To characterize plasma 24HC levels and change in seizure frequency in pat ients treated 
with TAK -935 as an adj unctive therapy
Rationale for Change :Because the primary  objective was changed to the Maintenance 
Period, the secondary  objective was changed to the Treatment period to evaluate the changes 
in seizure frequency that may potentially  occur earlier, i e, during the ent ire treatm ent peri od.
Consistent with the primary  objective/endpoint and give n the importance of the responder 
analysis, the frequency o f patients considered as treatment responders waschanged to the 
Maintenance Period (last 12 weeks of treatment).
The PK secondary  object ive of the correlat ion of 24HC levels wit h seizure frequency is more 
clinically meaningful.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 4. 2.2
ï‚·Secti on 10.9. 2
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 92of 10622. Revised the pharmacokinetic endpoints
Description of Change : The PK endpoints were revised as follows:
To determine the plasma concentrations of the TAK-935 and the TAK-935 metabolite 
(M-I) at multiple time points
Estimate exposure parameters from sparse PK samples using population modelling
Determine any potential relationship with estimated TAK-935 exposure parameters 
with changes in seizure frequency
Population pharm acokinetic parameter estimates (eg apparent clearance CL/F, apparent 
volume of distribution VD/F, Cmax, AUC, Cavg within dosing interval) at steady-state 
for TAK-935
Correlation of TAK-935 concentrations on th e serum levels of concomitant AEDs and 
their pharmacologically active metabolites
Outcome from an exposure-response model utilizing reduction in seizure rate for 
convulsive and drop seizures and TAK-935 concentrations
Rationale for Change : Estimate of exposure parameters using population modeling provides 
more clarification. Relationship between exposure and seizure frequency is more clinically 
meaningful.
Sections Impacted :
!Synopsis
!Section 4.2.4
!Section 10.11CCI
Property of Takconvuonvueda: For Non-Commercial Use Only and Srevised evised
ns of ths of th
from sprom sallattioionshnsercfrequenrequemcokinetcokinet iomutioion Vn VC
n of TAof TrharmacoarmacFo
tcomcome fedaonvulsonvuldS
ke
tionale ionale
moore clre c
meanmea
SdSs of Use
peSubject to the Applicable Terms
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 93of 10623. Revised and added analysis s ets
Description of Change : Deleted the statement that efficacy analysis would be based on the 
modified intent -to-treat (m ITT) analysis set. Added a definit ion for the new efficacy analysis 
set, defined asall m ITT pati ents whose efficacy  assessments are com pliant wi th protocol  
amendment 2.
Rationale for Change :To provide further clari ficati on on efficacy  analysis data set.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 10.4
24. Clarified and revised PK analyses
Description of Change : The plasma concentration -time and PD (24HC) data obtained in this 
study  will be used to estimate TAK -935 exposure param eters, analyze target engagement in 
terms of 24HC reduction, and evaluate potential relat ionships between TAK- 935 exposure or 
24HC responses and clinical and safet y endpo ints.Details will be included in a separate data 
analysis plan, and results wil l be reported separately.
Rationale for Change :To provide clarification on those parameters that are considered 
clinically meaningful.
Sections Impacted :
ï‚·Synopsis
ï‚·Secti on 8.1.22.3
ï‚·Secti on 10. 11
25. Updated study rationale 
Description of Change :Revised the summary statements for clinical stud yTAK -935-2001 
(OV935) (Phase 2a study ) to state that the study has been co mpleted.
Rationale for Change :Updated text to reflect th e current status of the study
Sections Impacted :
ï‚·Secti on 
3.2
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 94of 10626. Add new section to define end of the study
Description of Change :Added the fo llowing text:
The end o f the study  for an individual pat ient is defined as the last protocol -specified contact 
with that pati ent. The overall end of the study  is defined as the last protocol -speci fied contact 
with the l ast pati ent ongoing in the study .
Rationale for Change :To ensure sites had a clear understanding of what defined the end of 
the study  and to ensure consistency  with antecedent studi es.
Sections Impacted :
ï‚·Secti on 5.1.1
27. Simplified the background information provided for selection and timing of doses
Description of Change :Deleted Section 5.2.1 (Nonclinical Efficacy  and Saf ety) and 
Secti on5.2.2 (Clinical Safet y)
Rationale for Change :To remove informat ion that i s already  provided in the IB .
Sections Impacted :
ï‚·Secti on 5. 2.1
ï‚·Secti on5.2.2
28. Added 2 new forms of approved contraceptive methods
Description of Change :Added vasectomized partner and sexual abst inence as approved 
contraceptive methods.
Rationale for Change :Based on feedback fro m the clinical sites and IRBs.
Sections Impacted :
ï‚·Secti on 6.1
29. Added depression and/or suicidal ideation as a reason for study drug 
discontinuation
Description of Change : Added that depression and/or suicidal ideat ion coul d be a r eason for 
study  drug di scont inuat ionas assessed using the C -SSRS and with ultimate determinat ion of 
the presence o f suicidal ideation or behavior depending on the clinical judgment of the 
investigator
Rationale for Change : To be com pliant wi th patient safet y guidelines and for consistency  
within the protocol .
Sections Impacted :
ï‚·Secti on 6. 3.1
ï‚·Secti on 8.1.14
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 95of 10630. Added storage temperatures for ex -US sites
Description of Change :Added the fo llowing l anguage: 
For US si tes, TAK -935 tabl ets/mini -tablets must be stored at 20Â°C to 25Â°C (USP controlled 
room  temperature), wi th excursi ons permi tted f rom 15Â°C to 30Â°C. For sites in all other 
countri es, TAK -935 tabl ets m ust be stored at 1Â°C to 25Â°C.
Rationale for Change :The previous versio n of the protocol did not include storage 
temperatures for ex -US si tes, which are different from therecommended storage temperatures 
in the United States.
Sections Impacted :
ï‚·Secti on 7.1.1
31. Added that study drug may be shipped via courier service if patient is unable to 
come for clinic visit to obtain resupply
Description of Change : If a patient is unable to come for a clinic visit to ob tain study  drug, 
the study  drug may  be shipped via a courier service.
Rationale for Change : To ensure patients do not run out of study  drug in the event that they  
are unable to return to the clinic. 
Sections Impacted :
ï‚·Secti on 7.1
32. Clarified the handling of missed doses
Description of Change :Added the fo llowing text:
If a patient misses a dose, the missed dose should be skipped, and the patient should cont inue 
with his/her normal dosing schedule. Skipped doses should be reported as missed doses.
Rationale for Change :Based on inquiries from clinical sites, clarificat ion was required for 
proper instructions to study  patients on how to handle missing doses. Skipped doses should be 
reported as missed doses.
Sections Impacted :
ï‚·Secti on 7.2
33. Clarified how unblinding eve nts will be recorded and reported
Description of Change :Emergency  unblinding for AEs m ay be perform ed through an IWRS. 
Rationale for Change :Removed reference to em ergency codes being generated by  a 
computer drug -labeling system, as IWRS will serve this role.
Sections Impacted :
ï‚·Secti on 7.5
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 96of 10634. Changed demographic collection from â€œdate of birthâ€ to â€œyear of birthâ€
Description of Change :Updated the text clarifying that only year of birth will be co llected 
for dem ographics data collect ion.
Rationale for Change :To be com pliant wi th current pati ent privacy standards.
Sections Impacted :
ï‚·Secti on 8.1.2
35. Revised requirement for heart rate and blood pressure collection
Description of Change :Removed text that stated that heart rate and blood pressure will a lso 
be measured after 5 minutes supine and after 1 to 3 minutes standing, if possible.
Rationale for Change :Based on feedback fro m the clinical sites and to provide further 
clarificati on.
Sections Impacted :
ï‚·Secti on 8.1.6
36. Added a formula for assessmen t of seizure frequency
Description of Change :Added the fo llowing formula for assessment of seizure frequency: 
(# of seizures) / (# of days seizures were assessed) ï‚´28
Rationale for Change :The formula for seizure frequency  was not previ ously  noted in the 
protocol .
Sections Impacted :
ï‚·Secti on 8.1.7
37. Clarified the use of the dosing card
Description of Change :Added the text as fo llows to clarify the use of the dosing card: A 
dosing card wi ll be provi ded to the pati ent and/or caregiver at each clinic visit to record actual 
time of the last 2 dose administrations prior to PK sample collect ion, to record exact time of 
the last meal relat ive to dosing prior to PK or PD sample co llection, and to record any  changes 
in dosing regimen that may occur between visit s and during the de -escalat ion peri od of  the 
study; these will be recorded in the patientâ€™s source documents and transcribed into electronic 
case report form s(eCRFs) , including changes in d osing regimen (de -escalati on) that m ay 
occur between visits and during the de- escalat ion peri od of  the study .
Rationale for Change :The descript ion of the dosing card was inco mplete.
Sections Impacted :
ï‚·Secti on 8.1.8
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 97of 10638. Clarified that only sexually active female patients of childbearing potential will 
have pregnancy tests performed
Description of Change :Added the phrase â€œsexually act iveâ€ where needed to clarify that only 
sexually  active female patients of childbearing potent ial will have pregnancy  tests p erform ed.
Rationale for Change :As this patient populat ion includes patients of severely impaired 
facult ies, this change was made to reduce the clinical test burden on patients.
Sections Impacted :
ï‚·Secti on 8.1.11
ï‚·Secti on 8.1.12
ï‚·Appendix 1 ( Table 3)
ï‚·Appendix 2
39. Clarified the duration for avoidance of pregnancy and donation of ova/sperm for 
female and male patients
Description of Change :Added text to clarify that avo idance of pregnancy and donat ion of 
ova/sperm should be 90 day safter the last dose of study  drug.
Rationale for Change :The original text was not consistent with other sections of the 
protocol .
Sections Impacted :
ï‚·Secti on 8.1.12
40. Clarified pregnancy testing at Day 1
Description of Change :Added the fo llowing l angu age: If urine cannot be collected at Visit 2, 
the reason should be documented in the source document, the results of the serum pregnancy 
test obtained at Visit 1 must be confirmed to be negative by  the Invest igator prior to 
rando mizat ion, and the resul ts of a serum  pregnancy  test at Vi sit 2 m ust be confirmed to be 
negat ive before the patient can receive the first dose of study  drug.
Rationale for Change : Much of this language was already  present in Appendix 2 (now 
footnote c). Language was added to the other sections to ensure consistency ,and all 3 sect ions 
were updated to ensure that pregnancy test results are ob tained before female pat ients of 
childbearing potential receive study  drug.
Sections Impacted :
ï‚·Secti on 8.1.12
ï‚·Appendix 1 (Table 3)
ï‚·Appendix 2 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 98of 10641. Adding window for ECGs
Description of Change : For ECGs performed after the screening ECG (ie, after the start of 
dosing), the ECG will be recorded 30 min (Â±10 min) after the morning dose.
Rationale for Change : This sampling time point coincides with the C maxand T maxof 
TAK-935.
Sections Impacted :
!Section 8.1.13
!Appendix 1 (Table 3)
42. Clarified language for the C-SSRS administration
Description of Change : Removed text that indicated that a parent proxy could complete the 
C-SSRS. Clarified that trained study staff w ill administer the C-SSRS and that determination 
of the presence of suicidal ideation or beha vior depends on the clinical judgment of the 
investigator.
Rationale for Change : Revised for consistency with the instructional language on the 
C-SSRS.
Sections Impacted :
!Section 8.1.14
43. Clarified that the Exit survey is a separate questionnaire from the Care GI-C
Description of Change : Removed reference to the Care GI-C  in description of the Exit survey
Rationale for Change : Wording for exit survey previously was misinterpreted in the clinic.
Sections Impacted :
!Section 8.1.21
!Appendix 1 (Table 3)
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses
uld cold co m
d that dehat d
judgmjudg
ctiionalonalb
arate quarate q
e to the to th
it surveit surv
3)3)y
peperty of Takeda: For Non-C
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 99of 10645. Added statement about AEs or SAEs associated with overdose
Description of Change :Added the fo llowing text:
Adverse events (including S AEs) associated with overdose should be reported according to the 
procedure outlined in Sect ion 8.3.1.5. In the event of drug overdose, the patient should be 
treated symptomat ically.
Rationale for Change :Based on safet y guidelines, clarification on overdose is provided.
Sections Impacted :
ï‚·Secti on 8.3.1
46. Clarified reporting seizures as AEs/SAEs
Description of Change :Instructi on text for reporting seizures as AEs was revised fro m the 
following: 
For the purpose of this study , seizures will not be considered immediately  reportabl e as 
an(S)AEs unless: 1) there is a clear increase in frequency o f seizures co mpared to the pat ientâ€™s 
baseline, 2) there is an emergence of a new seizure ty pe, or 3) the patient experiences status 
epilept icus, and any other time the investigator feels the seizure should be captured as an 
(S)AE in which case the invest igator should document her/his r easoning.
To:
Seizures in this pat ient population will be measured using the seizure diary and seizure 
frequency  as a primary  study  endpoint (see Section 8.1.7). For the purpose of this study , 
reporting of seizures should meet the AE/SAE reporting requirements. As seizu res are 
considered a baseline condit ion, seizures should be reported as an AE/SAE if: 1) there is a 
clear increase in the frequency  of seizures co mpared to the patientâ€™s baseline, 2) there is an 
emergence of a new seizure t ype, or 3) the patient experience s status epilepticus, and any other 
time the Invest igator feels the seizure should be captured as an AE/SAE, in which case the 
Invest igator should document his/her reasoning. .
Rationale for Change :To provide clarification for the clinical sites on when se izures can be 
considered as AEs or SAEs .
Sections Impacted :
ï‚·Secti on 8.3.1
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 Ovid Therapeutics, Inc.
Date: 11 February 2019 
Page 100of 10647. Removed text that stated that expected SAEs were provided in the Investigatorâ€™s 
Brochure
Description of Change : Deleted the following text:
Information on SAEs e xpected in the study population independe nt of drug exposure and that 
will be assessed by the sponsor in aggregate periodically during the course of the study may be 
found in Appendix A of the current Investigatorâ€™s Brochure.
Rationale for Change : The current version of the Investigatorâ€™s Brochure does not include 
Appendix A, and the SAE information indicating as being included in The Investigatorâ€™s 
Brochure is not provided.
Sections Impacted :
!Section 8.3.1.3
48. Clarified SAE reporting process 
Description of Change : Clarified that AEs must be recorded in the eCRF upon awareness. 
Any AE that meets the criteria of an SAE must be reported to sponsor immediately using fax 
or email. Email address was updated to . If sites use the safety 
hotline telephone number to report an SAE, the site should first submit the SAE paper form 
and then enter the SAE in the eCRF. 
Removed AE reporting FAX numbers from the protocol and added a sentence stating that 
â€œcountry-specific FAX numbers will be provided in  a separate document.â€ Also removed AE 
reporting safety hotline telephone number from the protocol, and added a sentence stating â€œcountry-specific hotline numbers will be provided in a separate document.â€
Rationale for Change : To clarify that sites should submit the SAE paper form before entering 
the SAE in the eCRF and to state that country-specific FAX and safety hotline numbers will 
be provided to sites in a separate document.
Sections Impacted :
!Section 8.3.1.5
49. Added text stating that TAK-935 should not be administered to pregnant or 
lactating females 
Description of Change : Added the following text:
TAK-935 should not be administered to pregnant and lactating females because the potential 
for adverse reactions to TAK-935 in pregnant females, fetuses, and nursing infants is 
unknown.
Rationale for Change : Based on guidelines and feedback from the clinical sites.
Sections Impacted :
!Section 8.3.2CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee 
s s s
eCRF ueCRF
onsor imnsor i
. I
first subfirst su
ocol ancol an
d in a sepin a se
m the prm the pr
rovidedovide
sites shosites sh
at countrcoun
documeocumAp
tating ttating 
females male
of Chanf Cha
shoulhoulddederse rearse reak nownnown .fTRationRatio
SecSn
pebject
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 101of 10650. Added text on site responsibilities for record keeping
Description of Change :Added general text on how data records are to be kept or released 
during and after the study .
Rationale for Change :Based on GCP Guidelines .
Sections Impacted :
ï‚·Secti on 11
51. Updated the schedule of assessments 
Description of Change :All applicable revisio ns made in thebody  of the protocol  were 
implemented in the schedule of events, including the fo llowing:
Add addit ional phone calls
Clearly identify clinic visit s and phone calls
Revise study  day number to account for added weeks in Dose Optimization Period
Update time point and window for PK sampling and 12-lead ECGs 
Dispensing study  drug was added to Day  
141/ET (Visit 6) for pati ents not entering the 
OLE; study  drug return/accountabilit y/compliance was removed from  Day 1
Changed follow
-up from a phone call to clinic visit and added assessments to be 
perform ed at thi s visi t
Rationale for Change : Because the duration of treatment was changed to 20 weeks, 
additional study  visit s were incorporated. Other changes were implemented for c larificat ion.
Sections Impacted :
ï‚·Appendix 1 (Table 3)
52. Updated Appendix 2
Description of Change :Removed Perampanel and added Trileptal and Epi diolex to the list of 
concomitant AEDs and added alpha -1-acid glycoprotein to the list of serum chemistry  
analytes.
Rationale for Change :
To ensure the table shown in Appendix 2 accurately reflects the tests 
that will be performed by the central laboratory .Peram panel  was removed because it is now a 
prohibited medicat ion.
Sections Impacted :
ï‚·Appendix 2
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 102of 10653. Updated the Appendix 3 study sampling summary
Description of Change :Updated the maximum amounts per sample and the maximum 
number of samples.
Rationale for Change :To be consistent with the current laboratory  manual  for the study .
Sections Impacted :
ï‚·Appen dix 3
54. Replaced table in Appendix 3
Description of Change :Removed the previous table and inserted a new table for blood 
volume co llection of pediatric pat ients.
Rationale for Change :The previous table did not accurate lyreflect the blood volumes for the 
primarily pediatric populat ions in this study .
Sections Impacted :
ï‚·Appendix 3
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 103of 106AMENDMENT 1
1. Removal of â€˜Non -Dravet patients with convulsive seizuresâ€
Description of Change: Third stratum  of the study  is rem oved, and there will be only two 
strata Dravet syndrome and Lennox Gastaut syndrome.
Rationale for Change: Third stratum  of the study  was rem oved based on feedback received 
from the FDA to stratify  patients according to th eir individual DEE syndromes and reduce the 
number of syndromes in the study .
Sections Impacted:
Synopsis: Section 6.2.1
Secti on 6.2.2
Secti on 7.1
Secti on 9.3
Secti on 12.2
Secti on 12.3
Secti on 12.9.1
Secti on 12.9.2
Secti on 12.13
2. To change name of â€˜Drop seizureâ€™ stratum to â€˜LGS stratumâ€™
Description of Change: Name of Drop seizure stratum will be changed to LGS stratum
Rationale for Change: Based on feedback fro m the FDA the study  is limited to two 
syndro mes only , LGS and Dravet syndrome. Drop seizure str atum will only be limited to LGS 
patients and the name is changed accordingly .
Sections Impacted:
Synopsis
Secti on 6.2.1
Secti on 6.2.2
Secti on 7.1
Secti on 9.3
Secti on 12.2
Secti on 12.3
Secti on 12.9.1
Secti on 12.9.2
Secti on 12.13
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 104of 1063. To increase duration of maintenance period from 10 weeks to 12 weeks
Description of Change: Maintenance period of the study is increase fro m 10 weeks to 12 
weeks.
Rationale for Change: A 12 -week efficacy  assessment is anFDA requirement to properly 
evaluate maintenance of treatm ent effect. With the availabilit y of 9-month chronic toxicit y 
data, i t is now j ustified to extend the maintenance duration to 12 weeks.
Sections Impacted:
Synopsis
Secti on 7.1
Secti on 12.9.1
Secti on 12.9.2
Appendix 1 (Schedule of Assessments)
4. To allow administration of TAK -935 via gastrostomy tube (G- tube)/percutaneous 
endoscopic gastrostomy (PEG) tube
Description of Change: To cl arify administrati on of  TAK -935 in patients with G -or PEG -
tube.
Rationale for Change:
Approximately  30% of  pts wi th DEE canâ€™t swallo w oral medicat ions or eat food orally , so 
these patients are fed and administered medicat ion via gastric tube . Wit h the availabilit y of a 
CMC study  report showing that administration of TAK -935 i s viable through G -or PEG -tube, 
this opti on is justified.
Sections Impacted:
Secti on 9.2
5. Change in sample size the sample size
Description of Change:
The total sample size was changed from 152 to 112.
Rationale for Change:
Due to the reduction in the number of strata from 3 to 2 (above Changes 1 and 2), the total  
sample size was recalculated (Dravet stratum: 46 and LGS stratum: 80).
Sections Impacted:
Synopsis
Secti on 12.3
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 105of 1066. Remove exclusion criterion for status epilepticus (exclusion criterion #1)
Description of Change: To rem ove exclusio n of patients admitted to a medical facilit y and 
intubated for treatment of status epilept icus within 1 m onth of the Screening visit.
Rationale for Change: It was a repetit ive and created confusio n. Pati ents wi th frequent status 
epilept icus will  be excluded per exclusio n criterion #2
Section Impacted:
Synopsis
Secti on 8.2
7. Remove exclusion criterion for inability to swallow study drug safety (exclusion 
criterion #3)
Description of Change: Remove exclusio n based on the inabilit y to swa llow study  drug 
safet y by mouth
Rationale for Change: To allow administration of TAK -935 or pl acebo via G -tube/PEG tube 
after finalizat ion of CMC in vitro studies demo nstrating nearly 100% drug delivery through a 
G-tube when crushed and suspended in water.
Section sImpacted:
Synopsis
Secti on 8.2
8. Remove exclusion criterion for positive drug screen at screening
Description of Change: Remove exclusio n based on posit ive drug screen at Screening
Rationale for Change: Patients with history o f drug use di sorder woul d continue to be 
ineligible for the study , but screening for illicit drugs is remo ved. We were advised by clinical 
advisors and representative of pat ient foundat ions that majorit y of Dravet and LGS syndromes 
who have treatment resistant seizures will not be capable o f buying and using illicit drugs. 
And this test would result in an unnecessary  blood draw.
Sections Impacted:
Synopsis
Secti on 8.2
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Protocol TAK-935-2002 (OV935) Amendment 2 OvidTherapeutics, Inc.
Date: 11February  2019 
Page 106of 1069. BMI  assessment removed
Description of Change: Measurement of B MI at screening removed
Rationale for Change: Changes in percentile and abso lute weight and height of pediatric 
patients will  be used for assessment. BMI assessment was repeti tive, and its utilit y is less 
useful in pediatric patients compared to adult pati ents.
Sections Impacted:
Synopsis
Secti on 6.2.5
Secti on 10.1.5
Secti on 12.5
Secti on 12.10
Secti on 12.10.1
Appendix 1 (Schedule of assessments)
10. Perampanel added as a concomitant AED medication
Description of Change: Perampanel was added as a concomitan t AED m edicat ion for which 
plasma concentrations will be investigated
Rationale for Change: Level of perampanel was missed from  the list of AEDs in the original 
protocol .
Section Impacted:
Appendix 2
11. Patients with Hepatitis B and C are excluded
Description of Change: Patients will be excluded based on a history o f active hepat itis B or 
active hepat itis C infect ion.
Rationale for Change: Active Hepatit is B and C infect ion would not interfere with TAK -935 
administration or metabolism or effect ivene ss, therefore, patients will not be tested for 
hepat itis infect ion. However, patients with known hepat itis infect ion will be excluded. Other 
exclusio n criteria exclude patients with abnormal liver enzymes or unstable medical condit ions 
that coul d be caused by Hepat itis infection. Patients with Dravet and LGS syndromes with 
active hepat itis B and C would be known to their treating physicians because these are 
frequently seen in the clinics for their treatment resistant seizures.
Sections Impacted:
Synopsis
Section 8.2
Appendix 3 (Sampling summary)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use